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ABSTRACT 
Podocyte apoptosis is a hallmark in the development and progression of diabetic 
nephropathy (DN). Several factors of the diabetic milieu are known to induce 
podocyte apoptosis. Currently, the role of free fatty acids (FFAs) for podocytopathy 
and podocyte cell death is unknown, although FFAs are considered to be crucially 
involved in the development of diabetes mellitus type II. It is well known that FFAs 
are toxic to several cell types including pancreatic ß cells and they may contribute to 
the development of insulin resistance. The aims of this study were to elucidate the 
role of the saturated palmitic acid and the monounsaturated palmitoleic and oleic acid 
on podocyte cell death and endoplasmic reticulum (ER)-stress, to investigate more 
specifically the impact of ER-stress on podocyte survival as well as to elaborate 
strategies to protect podocytes from lipotoxicity. 
The present study uncovered that palmitic acid induces podocyte apoptosis and 
necrosis and leads to ER-stress as reflected by induction of the unfolded protein 
response (UPR), i.e. upregulation of the ER chaperone immunoglobulin heavy chain 
binding protein (BiP), X-box protein 1 (XBP-1) mRNA splicing, and a strong 
upregulation of the proapoptotic transcription factor C/EBP homologous protein 
(CHOP). Gene silencing experiments of CHOP support a crucial involvment of 
CHOP and ER-stress in mediating the proapoptotic effect of palmitic acid in 
podocytes. Contrariwise, monounsaturated FFAs (MUFAs) such as palmitoleic and 
oleic acid prevent palmitic acid-induced podocyte death and attenuate ER-stress. 
This study further revealed that the liver X receptor (LXR) agonist TO901317 (TO) 
ameliorates survival of palmitic acid-treated podocytes. Mechanistically, this 
beneficial effect can be explained mainly by the induction of stearoyl-CoA desaturase 
(SCD-) 1 and 2 as shown by gene silencing experiments and further supported from 
overexpression studies of SCD-1. Moreover, palmitic acid tracing experiments 
revealed a higher incorporation of palmitic acid into the triglyceride (TG) fraction in 
podocytes treated with TO or oleic acid, which is at least compatible with a benefit of 
increased fatty acid storage, by TO, i.e. SCDs, and MUFAs, respectively. 
In addition, this study provides some preliminary data that adenylate cyclases (AC) 
may be an interesting target to protect podocytes from ER-stress in general and in 
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particular from palmitic acid-induced podocytopathy and cell death. Experiments with 
forskolin, a specific AC agonist, and cyclic AMP (cAMP) analogons protect from 
palmitic acid-induced podocyte lipotoxicity. The effect cannot be explained by an 
involvment of PKA-CREB signaling as overexpression of a dominant negative CREB 
mutant could not abrogate the protective effect of forskolin. Furthermore, the 
beneficial impact of forskolin is not influencing the intrinisic (mitochondrial) 
apoptotic pathway. However, in addition to the protection from palmitic acid-induced 
cell death, forskolin is suppressing podocyte death caused by other independent ER-
stressors such as tunicamycin and thapsigargin. These findings suggest a direct role of 
forskolin and increased cAMP levels for a protection from ER-stress in podocytes. 
In summary, this study unveiled antagonistic effects of palmitic acid versus 
monounsaturated FFAs for podocyte survival, ER-stress and the UPR. They support 
an important role of CHOP in the regulation of podocyte death by FFAs. Similarly to 
exogenous MUFAs, induction of SCDs partially protects podocytes from palmitic 
acid-induced ER-stress and podocyte death. The protective effect of MUFAs may be 
related to increased incorporation of palmitic acid into TGs. Additional, preliminary 
data indicate that AC agonists such as forskolin may be interesting compounds to 
protect podocytes from ER-stress and from the toxic effects of FFAs. The results of 
this study offer a rationale for interventional studies aimed at testing whether dietary 
shifting of the FFA balance toward MUFAs, or tissue- (podocyte-) specific 
stimulation or overexpression of SCDs can delay the progression of DN. Similarly, 
the results of this study should encourage more studies to evaluate the therapeutic 
potential of AC agonists or phosphodiesterase inhibitors for the prevention and 
treatment of DN. 
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1. INTRODUCTION 
In the following I will highlight the relevance of diabetic nephropathy (DN) and I will 
give an introduction into its pathogenesis. Thereby, the main focus will lie on 
podocytes which are highly specialized epithelial cells of the glomerular filtration 
barrier and which are considered to play an important role in the pathogenesis of DN. 
In a second part I will outline causes and the pathophysiology of dyslipidemia, which 
is a hallmark of diabetes mellitus. Also, the distinct effects of saturated and 
unsaturated fatty acids on cell function and cell survival will be described in more 
detail.  
1.1 Diabetic nephropathy (DN): prevalence, pathogenesis and the 
role of podocyte injury 
1.1.1 Prevalence of diabetic nephropathy (DN): The most common cause of 
end-stage renal disease 
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease 
(ESRD) in industrialized countries, e.g. 44% in the US [1]. Although the progression 
to ESRD is less likely in patients with type II than with type I diabetes, the majority 
of diabetic patients starting renal replacement therapy today have type II diabetes as 
the prevalence of type II diabetes is much higher [1]. Of the patients with type II 
diabetes 20-40% develop ESRD [2]. The five-year survival rate of patients with DN 
and renal replacement therapy is significantly worse than in patients with other renal 
diseases mainly as a result of an increased cardiovascular mortality [1, 3]. Therefore, 
it is important to better understand the pathogenesis of DN, to identify new strategies 
and additional therapeutic targets for the prevention and treatment of DN. 
 
1.1.2 Pathogenesis of DN  
Dating back to the first description by Kimmelstiel and Wilson [4] histological 
analysis has focused on the increase in mesangial matrix as the main lesion of DN. In 
addition, glomerular basement membrane (GBM) thickening, and mesangial cell 
hypertrophy have been considered important pathophysiological events in the disease. 
However, the genesis of proteinuria in diabetes is not readily explained by the 
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associated mesangial expansion. Rather, consideration should be given to alterations 
of the glomerular filtration barrier. The glomerular filter consists of three layers: a 
fenestrated endothelium, the GBM, and the glomerular visceral epithelium cell or 
podocyte (Fig. 1). Podocytes are highly specialized cells forming primary processes, 
which are branching into secondary foot processes. Foot processes of neighboring 
podocytes interdigitate, leaving between them filtration slits that are connected by an 
extracellular structure, the slit diaphragm [5] 
 
 
Figure 1: Structure of the glomerular filtration barrier. The glomerular filter consists of 
three layers: a fenestrated endothelium, the glomerulare basement membrane (GBM) and the 
podocyte with their interdigitating foot process, the slit diaphragm. Picture adapted from 
website of Karolinska Institute, Stockholm, Sweden. 
1.1.3 The role of podocytes in the pathogenesis of DN 
Over the past two decades by elucidating the genetic origin of a number of single 
human gene defects that result in congenital or early onset nephrotic syndrome, it has 
become apparent that the final barrier restricting plasma proteins to the vasculature is 
the podocyte [6, 7]. Also, damage to podocytes has been linked to many renal 
diseases that often progress to ESRD [8]. However, little research has been conducted 
on podocyte biology in diabetes until recently. 
Podocytopathy in DN is characterized by foot process widening which was shown to 
correlate in microalbuminuric type I diabetic subjects with the urinary albumin 
excretion rate [9]. In addition to foot process widening, the number and density of 
podocytes have been reported to be decreased in patients with type I or type II 
diabetes [10-14]. This podocyte loss clearly relates to elevated proteinuria [15]. The 
mechanism underlying proteinuria can be explained by the lack of charge and size 
selectivity in areas of podocyte loss. In Pima Indians with type II diabetes the reduced 
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number of podocytes per glomerulus was the strongest predictor of progressive 
kidney disease [16].  
As podocytes have no or very limited ability to replicate [17] two mechanisms remain 
for the loss of podocytes in diabetes: apoptosis and/or cell detachment. The later 
scenario does not exclude a role of apoptosis, since cells may first detach and then 
undergo apoptosis or vice versa (anoikis = apoptosis caused by loss of attachment of 
cells to their basement membrane). Alternatively, detached cells can be shed in the 
urine as viable podocytes [18, 19]. In patients with type II diabetes podocyturia 
worsens with the progression from normoalbuminuria to microalbuminuria and to 
overt proteinuria [20].  
 
Viable podocytes have also been isolated in the urine of DN-induced rats [18]. 
Podocytes are connected on the basolateral membrane to the GBM via integrins (? 
and ß subunits) [21] and dystroglycans [22]. Decreased levels of ?3ß1 integrins have 
been found in patients with DN and streptozotocin-induced diabetic rats [23], and 
altered expression of dystroglycan 1 has been observed in early DN of db/db mice, a 
type II diabetes model [24]. 
 
The second cause leading to a reduction in podocyte number is apoptosis. The 
decision whether a cell undergoes apoptosis can be seen as an imbalance between 
proapoptotic and survival factors. Data are increasing with the focus on factors that 
are altered in the diabetic milieu and shifting the cell fate towards apoptosis. 
 
Factors contributing to apoptosis of podocytes in DN 
In diabetes various factors are altered and contribute to the diabetic milieu. Several of 
these factors have been shown to damage the glomerulus and to influence directly 
podocyte survival. Among these factors are hyperglycemia, advanced glycated end 
products (AGEs), insulin resistance, TGF-ß and angiotensin II. 
Susztak and coworkers demonstrated that podocyte apoptosis is coinciding with the 
onset of diabetes in a type I diabetes (Akita mice) and a type II diabetes model (db/db 
mice) [25]. Furthermore they could show that hyperglycemia itself induces apoptosis 
in cultured podocytes via accumulation of reactive oxygen species (ROS). 
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Accordingly apocynin, a NADH oxidase inhibitor, could partially block podocyte 
depletion and proteinuria in diabetic mice [25]. 
In addition prolonged exposure of proteins to glucose leads to the formation of AGEs. 
In diabetes, tissue levels of AGEs are elevated [26]. In podocytes, AGEs result in 
increased expression of transforming growth factor ß (TGF-ß) and vascular 
endothelial growth factor (VEGF) [27]. Finally, AGEs lead to apoptosis involving the 
nuclear transcription factor FOXO4 [28] and endoplasmic reticulum (ER)-stress [29]. 
A recent study examined defective podocyte insulin signaling in vivo and it has been 
observed that insulin signaling itself is crucial for proper glomerular function. 
Podocyte-specific insulin receptor knockout mice are albuminuric at week 8 and show 
morphological changes of the glomerulus with loss of podocyte foot processes and 
increased apoptosis of podocytes [30]. 
The renin-angiotensin-aldosterone system (RAAS) is also critically involved in the 
pathogenesis of DN. Angiotensin II acts directly on the glomerulus by inhibiting 
mesangial matrix degradation [31]. Furthermore, angiotensin II is inducing podocyte 
apoptosis, potentially mainly through increased production of TGF-ß [32]. TGF-ß, a 
cytokine involved in tissue repair is known to be elevated in DN [33], leading to 
extracellular matrix expansion and consequently contributing to progressive 
glomerulosclerosis [34, 35]. Transgenic mice overexpressing TGF-ß show glomerular 
abnormalities at three weeks of age and mice with the highest levels of TGF-ß 
developed proteinuria after five weeks [35]. In the same mouse model podocyte 
number gradually decreased within five weeks. In vitro TGF-ß induces apoptosis in 
podocytes via activation of the proapoptotic mitogen-activated protein (MAP) kinase 
p38 [36]. 
 
1.2 Pathophysiology of dyslipidemia in obesity and type II diabetes: 
causes and consequences of lipotoxicity 
Apart from hyperglycemia and insulin resistance type II diabetes is characterized by 
altered blood lipid levels or dyslipidemia. In type II diabetes dyslipidemia is mainly 
manifested by increased lipid content (hyperlipidemia) such as hypertriglyceridemia 
and elevated plasma free fatty acids (FFAs). Contrariwise, increased plasma FFAs are 
critically involved in the pathogenesis of type II diabetes. Obesity is associated with 
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markedly increased plasma FFA, which is considered a major contributor to the 
development of type II diabetes [37, 38]. 
1.2.1 Disturbed lipid metabolism in obesity and type II diabetes 
Under healthy conditions energy substrate metabolism is tightly controlled by 
endocrine and paracrine factors, e.g. insulin and catecholamines, to adjust energy 
availability to the particular needs. In general, availability of glucose is inhibiting 
lipolysis in fat cells (adipocytes) and fatty acid oxidation in tissue. In the fasted state, 
lipolysis is activated and provides fatty acids, or ketone bodies, which are produced 
by the liver. Both, fatty acids and ketone bodies are delivered as energy substrates to 
tissues [39, 40]. 
Obesity is caused by an imbalance of energy intake and expenditure leading to 
enlarged adipocytes (hypertrophy) and/or an increased adipocyte number 
(hyperplasia). Hypertrophy results from augmented storage of triglycerides (TGs) in 
lipid droplets. Enlarged, “saturated” adipocytes show decreased sensitivity towards 
the action of insulin, they release an increased amount of fatty acids, and they secrete 
inflammatory cytokines (adipokines) [41-43]. Adipokines are recruiting macrophages, 
which further amplify the inflammatory response [44]. The increased release of fatty 
acids from adipocytes elevates plasma FFA concentrations further, finally resulting in 
enhanced overspilling of fatty acids to non-adipose tissue [45, 46]. Constant exposure 
of non-adipose tissue to high levels of FFAs leads to accumulation of toxic 
metabolites such as diglycerides (DAGs) and ceramides. The associated cellular 
dysfunctions are referred to as lipotoxicity. Lipotoxicity aggravates insulin resistance, 
disrupts pancreatic ß cell function (insulin secretion), and ultimately leads to 
programmed cell-death (lipoapoptosis) [46]. Once the compensatory hyperinsulinemia 
characteristic of obese, insulin-resistant individuals cannot be maintained as a result 
of pancreatic ß cell failure, hyperglycemia i.e. type II diabetes manifests [45, 47, 48]. 
 
1.2.2 FFA lipotoxicity: opposing effects of saturated – and monounsaturated 
fatty acids 
Up to 80% of the plasma FFAs consist of the saturated palmitic (C16:0) and stearic 
acid (C18:0), and the monounsaturated oleic acid (C18:1) [49]. Lipotoxicity has been 
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attributed mainly to saturated long chain fatty acids (SFAs) whereas monounsaturated 
fatty acids (MUFAs) exert beneficial and cytoprotective effects [50]. 
Adipocytes are naturally not susceptible to apoptosis induced by SFAs but they 
become insulin resistant and they express inflammatory cytokines [51]. However, 
preadipocytes with its little capacity to synthesize and store lipids undergo apoptosis 
when treated with palmitic acid [52]. Furthermore, exposure to palmitic acid is 
initiating insulin resistance and/or apoptosis in pancreatic ß cells [48, 53-56], skeletal 
muscle cells [57, 58], cardiomyocytes [59, 60], hepatocytes [61-63], endothelial cells 
[64] and some breast cancer cells [65]. 
Palmitic acid-induced insulin resistance in hepatocytes has been attributed to 
increased reactive oxygen species (ROS) resulting from ß-oxidation. ROS lead to 
phosphorylation and activation of c-Jun NH2-terminal kinase (JNK) that is inhibiting 
insulin-stimulated tyrosine phosphorylation of insulin receptor substrate 2 (IRS-2) and 
subsequent serine phosphorylation of Akt via alternate threonine phosphorylation of 
IRS-2 [63, 66]. Alternatively, studies in skeletal muscle cells have shown that 
activation of protein kinase C isoforms by lipid metabolites such as DAGs and 
ceramide, inhibit insulin signaling by either serine phosphorylation of IRS-1 or by 
threonine phosphorylation of Akt [67]. In a recent study, JNK activation and insulin 
resistance have been causatively linked to the membrane-anchored tyrosine kinase c-
Src. SFAs are leading to c-Src partitioning into membrane microdomains where c-Src 
likely becomes phosphorylated, which leads to phosophorylation and thereby 
activation of JNK [68]. Long-term exposure of cells to SFAs is generally causing 
apoptosis. Apoptosis has been linked, at least in part, to accumulation of ceramides 
and ROS that eventually induce the activation of the apoptotic machinery [53, 69]. 
In contrast, MUFAs are in general non-toxic and prevent from SFA-induced cell 
damage. The cytoprotective actions of MUFAs and their underlying mechanisms are 
not completely understood [50]. However, on one side MUFAs are more potent 
ligands of the peroxisome proliferator-activated receptor ? (PPAR?), a transcription 
factor regulating lipid metabolism [70]. PPAR? is inducing transcription of genes 
involved in peroxisomal and mitochondrial ß-oxidation [71]. Hence, MUFAs are 
thought to detoxify cells from SFAs by increasing ß-oxidation. On the other side, 
coincubation of MUFAs and SFAs has been shown to restore TG synthesis as SFA-
derived long chain acyl-CoAs are not incorporated into TGs very efficiently [65, 72]. 
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It is thought that storage of SFAs in TGs prevent from the accumulation of toxic 
metabolites. Furthermore cotreatment restores levels of cardiolipin that, if reduced, 
results in increased cytochrome c release from mitochondria [65].  
Associated with the distinct effects of SFAs and MUFAs is the initiation of 
endoplasmic reticulum (ER)-stress and the resulting activation of several signaling 
pathways, collectively known as unfolded protein response (UPR) [73].  
 
1.2.2.1 ER-stress and the unfolded proteins response (UPR) 
The ER is the organelle where secreted, membrane-bound and some organelle-
targeted proteins are synthesized and folded. Optimal folding conditions require Ca
2+
, 
ATP and an oxidizing environment to enable disulfide bond formation. As a 
consequence, the ER is highly sensitive to changes in Ca
2+
 and energy levels as well 
as in redox state [74, 75]. Such changes are reducing the folding capacity of the ER 
and thereby leading to an accumulation of unfolded and/or misfolded proteins, a 
condition that has been termed ER-stress. Cells have evolved strategies to counteract 
the detrimental effects of ER-stress, referred to as the UPR (Fig. 2). The UPR cascade 
is involving three signaling branches that are mediated by ER transmembrane 
receptors: double-stranded DNA-dependent protein kinase (PKR)-like ER kinase 
(PERK), inositol-requiring enzyme 1 (IRE-1), and activating transcription factor 6 
(ATF6). 
In the resting state the receptors are bound by the ER chaperone immunoglobulin 
heavy chain binding protein (BiP, also termed GRP78 or HSPA5) that keeps them 
silenced. Accumulation of unfolded and/or misfolded proteins is leading to 
dissociation of BiP and therefore to the activation of PERK, IRE-1 and ATF6. 
PERK is dimerizing and autophosphorylation results in phosphorylation of eukaryotic 
initiation factor 2 that is inhibiting protein translation [76]. One of the genes not 
affected by this process is ATF4, a transcription factor which upregulates genes 
involved in stress response, redox reactions and amino acid metabolism [75, 77]. 
IRE-1 activation is occurring by oligomerization and its endoribonuclease domain is 
removing a 26 nucleotide long intron of X-box binding protein 1 (XBP-1) mRNA 
[78]. The spliced form of XBP-1 is an active transcription factor and binds to 
promoter elements to activate transcription of ER chaperones, ER associated protein 
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degradation (ERAD) factors and factors involved in ER membrane biogenesis [79-
82]. 
Finally, dissociation of BiP leads to the transport of ATF6 to the Golgi where 
cleavage and release of the cytosolic domain takes place [79, 83, 84]. ATF6 
translocates to the nucleus to activate transcription of target genes as chaperones and 
XBP-1. 
If normal ER function cannot be restored apoptosis is initiated mainly by the 
transcription factor C/EBP homologous protein (CHOP). The promoter of CHOP 
contains binding sites for all three branches of the UPR: ATF4, ATF6 and XBP-1 
[85]. However, the molecular mechanisms of CHOP-mediated apoptosis are not 
completely understood. Nevertheless CHOP has been linked to reduced expression of 
antiapoptotic Bcl-2, hyperoxidized ER lumen and calcium-related apoptotic signaling 
[86]. 
 
Figure 2: The unfolded protein response (UPR), adapted from [75]. After accumulation 
of un- and misfolded proteins, the ER chaperone BiP is dissociating from the three ER 
transmembrane receptors, PERK, IRE-1 and ATF-6, which are transmitting the ER-stress 
response. The UPR is leading to translational block, increased protein degradation and to 
expression of ER chaperones (e.g BiP). If ER-stress is persistent apoptosis is initiated, which 
is mainly executed by the transcription factor CHOP. PERK, PKR-like ER kinase; IRE-1, 
inositol-requiring enzyme-1; ATF6, activating factor 6; BiP, immunoglobulin heavy chain 
binding protein; CHOP, C/EBP homologous protein. 
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1.2.2.2 FFA-mediated ER-stress 
Exposure to FFA is inducing ER-stress and initiating the UPR in several cell types. 
SFAs and MUFAs show quantitatively and qualitatively distinct or even opposite 
effects, i.e. MUFAs are protecting cells from the proapoptotic actions of SFA-induced 
ER-stress. Palmitic and oleic acid are rapidly incorporated into the ER membrane but 
only palmitic acid is leading to changes in ER structure and integrity [87]. Palmitic 
acid increases the saturated lipid content and compromises ER integrity, which is 
thought to trigger ER-stress. Of interest, overexpression and induction of ER-located 
stearoyl-CoA desaturases (SCDs), which catalyze the ?9-desaturation and thus the 
conversion of SFAs to MUFAs, have been shown to attenuate palmitic acid-induced 
ER-stress and apoptosis [88-90]. 
 
In pancreatic ß cells, SFAs such as palmitic acid are activating all three branches of 
the UPR, PERK, IRE-1 and ATF-6. PERK and IRE-1 signaling are mainly 
responsible for the upregulation of the proapoptotic transcription factor CHOP [91]. 
In addition IRE-1 is activating JNK [91]. Both, CHOP and JNK, have been shown to 
be partially responsible for palmitic acid-induced pancreatic ß cell apoptosis [91]. In 
contrast, MUFAs such as oleic acid are exclusively triggering ATF-6 signaling, which 
is inducing the ER chaperone BiP [91]. Moreover, oleic acid is preventing pancreatic 
ß cells from palmitic acid-induced CHOP induction and JNK activation [91, 92]. 
These differences might explain the distinct actions of SFAs and MUFAs on cell 
lipotoxicity [93]. 
A similar picture has been observed in hepatocytes. Palmitic acid leads to an 
induction of CHOP and to JNK activation. CHOP-silencing revealed that CHOP can 
delay palmitic acid-induced hepatocyte apoptosis whereas inhibition of JNK signaling 
could suppress apoptosis [94]. Oleic acid is not inducing ER-stress but, consistently, 
prevented hepatocytes from palmitic acid-induced ER-stress [61]. 
In skeletal muscle cells, palmitic acid-induced ER-stress has been linked to impaired 
insulin signaling and oleic acid has been shown to block this effect by preventing 
from palmitic acid-induced abnormal cellular lipid composition and distribution [95]. 
Overall, ER-stress is thought to be crucially involved in FFA-mediated and in 
particular SFA-mediated lipotoxicity. 
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1.3 Aim of the study 
As outlined before, podocytopathy is an early feature in the pathogenesis of DN and a 
decreased number of podocytes per glomerulus predicts progressive renal disease in 
type II diabetes patients [16]. Several factors of the diabetic milieu have been 
associated with podocyte dysfunction and/or apoptosis but very little is known about 
the role of dyslipidemia and FFAs on podocyte function and survival.  
In vitro, SFAs in contrast to MUFAs are causing insulin resistance and/or apoptosis in 
several cell types and SFA-mediated lipotoxicity involves ER-stress. Importantly, ER-
stress has been associated not only with the development of diabetes [86, 96, 97], but 
also with renal dysfunction [98]. 
The objectives of this study were to investigate the regulation of podocyte survival 
and ER-stress by fatty acids. More specifically, I explored the impact of the saturated 
palmitic acid and MUFAs, such as oleic and palmitoleic acid, on podocyte death and 
the involvment of ER-stress herein. Moreover, I investigated the role of cell 
autonomous conversion of SFAs into MUFAs by studying the impact of stearoyl-CoA 
desaturases, which catalyze the ?9-desaturation of SFA and thereby convert them to 
MUFAs. In addition, I examined the potential of elevated cAMP levels in preventing 
palmitic acid-induced podocyte death. 
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2. MATERIALS AND METHODS 
2.1 Cell culture 
Podocytes were cultured as described before by Mundel et al. [99, 100]. Briefly, 
conditionally immortalized podocytes were cultured under permissive conditions 
(33°C) in RPMI-1640 (#21875, Invitrogen) supplemented with 10% FBS (#10270, 
Invitrogen), 100 U/ml penicillin and 100 ?g/ml streptomycin (#15140, Invitrogen) 
and interferon-? (Cell Sciences) on type I collagen (BD Biosciences). Induction of 
differentiation is mediated by a thermo shift to 37°C without interferon-? in 6-well 
plates (apoptosis assays, mRNA isolation, and lipid and ß-oxidation analysis) and 
10cm dishes (protein isolation). Experiments were performed at least at day 11 of 
differentiation. 
HEK293 cells were cultured in DMEM (#41965, Invitrogen) supplemented with 10% 
FBS and penicillin/streptomycin.  
2.2 Agonists, inhibitors, analogons and cytokines 
The following agonists, inhibitors and compounds were used at the indicated 
concentrations (Table 1). 
Substance Product number # Supplier Action Concentration 
4-PBA 567615 Calbiochem Chemical chaperone 0.5 mM 
8-Br-cAMP B7880 Sigma cAMP analogon 100-200 ?M 
8-CPT-2Me-cAMP 116833 Calbiochem cAMP analogon 200 ?M 
Forskolin F6886 Sigma AC agonist 1 ?M 
H89 371963 Calbiochem PKA inhibitor 2-10 ?M 
Staurosporine 1048 BioVision General kinase inhibitor 0.25 ?M 
TGF-ß 100-21C PeproTech  5 ng/ml 
Thapsigargin 586005 Calbiochem SERCA inhibitor 1 ?M 
TO901317 71810 
Cayman 
Chemical 
LXR agonist 1 ?M 
TUDCA 580549 Calbiochem Chemical chaperone 0.25-5 mM 
Tunicamycin T7765 Sigma 
GlcNAc 
phosphotransferase 
inhibitor 
2-5 ?g/ml 
Table 1: Agonists, inhibitors and compounds with their applied 
concentrations 
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2.3 Fatty acid preparation 
Fatty acid preparation was applied by two different methods as described in 
Listenberger et al. (2001) and Maedler et al. (2001) [53, 69]. 
First, a 20 mM solution of palmitic or palmitoleic acid in 0.01 M NaOH (vehicle) was 
incubated at 70°C for 30 min and complexed to 10% BSA in a molar ratio of 6.6:1, 
shaken overnight at 37°C under N2-atmosphere, sonicated for 10 min, sterile filtrated 
and stored at -20°C; the complexes were heated at 60°C for 15 min before use 
followed by dilution in culture medium. 
Second, sodium palmitate, palmitoleic or oleic acid (all from Sigma) were dissolved 
overnight at 10 mM in glucose-free RPMI-1640 medium (#11879) containing 11% 
essential fatty-acid free BSA (Sigma) under N2-atmosphere at 55°C, sonicated for 10 
min and sterile filtered (stock solution). The molar ratio of fatty acid to BSA was 6:1. 
The effective free fatty acid concentrations were measured with a commercially 
available kit (Wako). 
Both applications revealed comparable results but the second approach became the 
method of choice. 
2.4 Apoptosis assay 
The cells were trypsinized, washed once with PBS, and resuspended in 120 ?l 
annexin V binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). 
100 ?l of the cell suspension was used for the staining procedure. Alexa-647 annexin 
V (Invitrogen) staining was applied for 15 min at room temperature at a dilution of 
1:100 (see producer protocol) and before analyzing an additional 400 ?l of annexin V 
binding buffer and 0.5 ?g propidium iodide (Invitrogen) were added. 20’000 – 25’000 
cells were analyzed by flow cytometery (Beckman Coulter) [101]. Annexin V single 
positive cells were counted as apoptotic cells and annexin V and PI double positive 
cells were counted as (late apoptotic) necrotic cells.  
2.5 Cytochrome c release 
The cells were washed twice with ice cold PBS and incubated for 10 min on ice in 
digitonin lysis buffer (75 mM KCl, 1 mM NaH2PO4, 8 mM Na2HPO4, 250 mM 
sucrose and 190 ?g/ml digitonin) in the presence of EDTA-free protease inhibitors 
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(Roche). The cytosolic fraction was collected and spun down at 500xg for 5 min at 
4°C to remove cell debris. The supernatant was further analyzed by Western blotting. 
2.6 Vectors and lentivirus production 
2.6.1 Knockdown 
A) Specific 21-nt CHOP oligonucleotides (see table 2) were cloned into a CMV 
vector (BbSI/BstBI) under an ubiquitin (U6) promoter. In a second step the U6-21-nt-
oligonucleotides were cloned into a FUGW vector (BstBI/NheI) coexpressing GFP. A 
21-nt scrambled sequence with no significant mammalian homology was applied as a 
control [101]. 
B) Specific SCD1 and SCD2 shRNAs in a PLKO.1 puro vector were obtained from 
Sigma. 
 
Gene shRNA sequence Vector GeneBank 
number 
CHOP GGAAACGAAGAGGAAGAATCA FUGW NM_007837 
CHOP (2) GGCGGGCTCTGATCGACCGCA FUGW NM_007837 
Scrambled GACCGCGACTCGCCGTCTGCG FUGW  
Scrambled (2) GACCGCATAGATACTAGACCC FUGW  
SCD1 GCCTTTAATCAACCCAAGAAA PLKO.1 puro NM_009127 
SCD1 CCTACGACAAGAACATTCAAT PLKO.1 puro NM_009127 
SCD1 AGTTTCTAAGGCTACTGTCTT PLKO.1 puro NM_009127 
SCD2 GAACATTAGCTCTCGGGAGAA PLKO.1 puro NM_009128 
SCD2 CGCGTATTTGTACTATGTAAT PLKO.1 puro NM_009128 
Table 2: shRNA sequences and the particular vectors. 
2.6.2 Overexpression 
2.6.2.1 SCD-1 
The whole murine SCD1 sequence under a CMV promoter in an EZ-Lv153 vector 
was purchased from GeneCopoeia. GFP in a pLVX-puro vector, as well under a CMV 
promoter, was used as a control. It was kindly provided by Dr. Dennis Pfaff 
(University Hospital Basel, Switzerland). 
  14 
2.6.2.2 ACREB 
ACREB [102] was kindly provided by Prof. Handschin (University of Basel, 
Switzerland). The sequence was amplified with two primers (5’-
ATAATTTCGAACGGTGGGAGGT-3’, 5’-AGAAGGCACAGTCGAGGCTG-3’) 
and cloned into the vector pLVX-puro using the restriction sites BstBI and XbaI. 
2.6.3 Lentivirus production 
Lentivirus production was performed as previously reported by Dittgen et al. 2004 
[103]. In brief, HEK293 cells (30-40% confluency in a T175 cm
2
 flask (BD falcon)) 
were transfected using Fugene (Roche) with the expression (1 ?g) and two helper 
plasmids, vesicular stomatitis virus (VSV) G protein (5 ?g) and ?8.9 (7.5 ?g). The 
particular plasmids were added to a mixture of 45 ?l Fugene and 500 ?l Opti-MEM 
(Invitrogen), incubated for 15 min at room temperature and subsequently added to 
HEK293 cells in 20 ml culture medium (see part 2.1). 12 hours after transfection 
medium was exchanged and after 72 hours the supernatant was spun down at 780xg, 
filtered at 0.45 ?m pore size and stored at -80°C. 
Podocytes were transduced by adding virus-containing medium after five minutes 
pretreatment with 10 ?g/ml Polybrene (Sigma). 8-24 hours after transduction medium 
was exchanged. Experiments were performed three to five days after viral 
transduction. 
2.7 Western blot 
Podocytes were washed with ice cold PBS and scraped in 200 ?l RIPA lysis buffer 
(50mM Tris-HCl, pH 7.5, 200 mM NaCl, 1% Triton, 0.25% deoxycholic acid, 1 mM 
EDTA, 1mM EGTA) containing EDTA-free protease inhibitors (Roche) and 
phosphatase inhibitors (Pierce). To include the floating and detached cells, the culture 
medium and PBS (the cells were washed with) were collected, centrifuged (530xg) 
and resuspended in 20 ?l lysis buffer. The pooled cells were lysed mechanically and 
rotated for 1 h at 4°C. To remove nuclei, the samples were spun down (10’000 rpm, 
10 min) and the protein concentration of the supernatant was determined by DC 
Protein Assay (Bio-Rad). 20 - 80 ?g of protein was complemented with 6x sample 
buffer (200 mM Tris-HCl pH 6.8, 26% glycerol, 10% SDS, 0.01% bromphenol blue) 
and DTT (final concentration of 100 mM) and heated for 10 min at 95°C. Protein 
samples were loaded on 12-15% gels and SDS-PAGE was performed at 200 V. 
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Transfer to nitrocellulose membranes (Protran BA83, Whatman Schleicher und 
Schuell) was applied at 100 V in the coldroom for 1 hour and the blots were blocked 
for 2 hours with 5% milk powder in TBS-Tween (50 mM Tris HCl pH 7.4, 150 mM 
NaCl, 0.02% Tween). Primary antibodies were applied overnight and the secondary 
antibodies for 1 hour at the indicated dilutions in 5% milk in TBS-Tween (Table 3). 
The immunoblots were detected by enhanced chemiluminescence (Pierce) on Kodak 
BioMax light films (Sigma). 
Antigen Species Conjugate Supplier Application Dilution 
Akt Rabbit Purified Cell signaling WB 1:1000 
Bcl-2 Rabbit Purified Cell Signaling WB 1:1000 
BiP Rabbit Purified Cell signaling WB 1:500 
Caspase 3 Rabbit Purified Cell signaling WB 1:100 
CHOP Mouse Purified Santa Cruz WB 1:200 
CREB Rabbit Purified Cell Signaling WB 1:1000 
Cytochrome c Mouse Purified BD Bioscience WB 1:3000 
Flag Mouse Purified Sigma WB 1:2000 
Mouse IgG Goat antiserum HRP Jackson WB 1:2000 
P-Akt Rabbit Purified Cell Signaling WB 1:500 
P-CREB Rabbit Purified Cell Siganling WB 1:500 
Rabbit IgG Goat antiserum HRP Dako WB 1:1600 
ß-actin Mouse Purified Sigma WB 1:50’000 
Table 3: The specific antibodies and the applied concentrations. 
2.8 Quantitative Reverse Transcription PCR (XBP-1 splicing) 
Total RNA was extracted with a Nucleospin kit (Macherey-Nagel GmbH) and first-
strand cDNA was synthesized using oligo(dT) primers (Fermentas). The mRNA (0.5-
2 ?g) and oligo(dT) (0.5 ?g) mix (Vtot = 12.5 ?l) was heated at 70°C for 5 min and 
put on ice for 4 min. After addition of 5x RevertAid™ reaction buffer, dH2O, RNAse 
inhibitor (20 U), dNTPs (1 mM) and RevertAid™ Reverse Transcriptase (50 U; all 
from Fermentas) reverse transcription (Vtot = 20 ?l) was performed at 42°C for 60 
min and a final step at 72°C for 10 min. 
cDNA (1?l) was amplified in a total volume of 10 ?l: 1 ?l dNTP mix (10 mM each, 
Sigma) 1 ?l of each primer (20 mM, see table 4), 1 ?l 25 mM MgCl2 (Promega), 2 ?l 
Promega 5x Buffer, 3 ?l dH2O and 0.2 ?l Taq Polymerase (Promega). Amplification 
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was performed with an initial denaturation at 94°C for 1 min, 30 cycles of PCR at 
94°C for 30 s, 58°C for 30 s and 72°C for 1 min, and a final extension at 72°C for 10 
min. ß-actin was applied as a control. PCR products were separated by electrophoresis 
on 2.5% agarose gels in TAE running buffer (40 mM Tris acetate pH 8, 1 mM 
EDTA), stained for 10 min in 2 ?g/ml ethidium bromide (Sigma) and visualized by 
UV light. 
2.9 Quantitative real-time PCR (SCD expression) 
After cDNA synthesis (see part 2.7), real-time PCR was performed in a total volume 
of 20 ?l using 2x GoTaq® qPCR Master Mix (Promega) and 0.75 ?M of the 
particular primers (see table 4). GAPDH and ß-actin were used as internal controls. 
The experiments were carried out in a 7500 Fast Real Time PCR System (Applied 
Biosystems) with an initial denaturation at 95°C for 10 min and 40 cycles of 
amplification (95°C for 15 sec and 60°C for 1 min).  
 
Gene Primer Sequence (5’-3’) Product 
Length (bp) 
GeneBank 
number 
Reference 
XBP-1 Fw- TGAGAACCAGGAGTTAAGAACACGC 
Rv- TTCTGGGTAGACCTCTGGGAGTTCC 
u
*
: 330 
s
*
: 304 
AF027963 [104] 
SCD-1 Fw-TCTTGTCCCTATAGCCCAATCCAG 
Rv-AGCTCAGAGCGCGTGTTCAA 
130 NM_009127 [105] 
SCD-2 Fw-AGTGTTGCTCGTGAGCCTGTG 
Rv-CCTGCAGATCCATGTCCAGCTA 
140 NM_009128 [105] 
SCD-3 Fw-TCACACCGTGAACCCTGAGATTGT 
Rv-TGCTTGCTCTGCCTCTTGACCTAT 
160 NM_024450 [105] 
SCD-4 Fw-ACCTTGCTCTCTCTGCCTTCACAA 
Rv-TGCTGGAGATCTCTTGTGGCAAGT 
84 NM_183216 [105] 
ß-actin Fw-GAAATCGTGCGTGACATCAAA 
Rv-GTGCACCGCAAGTGCTTCTAG  
510 NM_007393  
GAPDH Fw-CTGCACCACCAACTGCTTAGC 
Rv-GGCATGGACTGTGGTCATGAG 
88 NM_008084  
Table 4: Specific primer sequences. 
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2.10 Quantitative real-time PCR of renal biopsies 
Experiments were performed by the group of Prof. Cohen at the University of Zurich. 
Human renal biopsy specimens were procured in an international multicenter study, 
the European Renal cDNA Bank-Kroener-Fresenius Biopsy bank (ERCB-KFB). 
Biopsies were obtained from patients after informed consent and with approval of the 
local ethnics committees. Following renal biopsy, the tissue was transferred to RNase 
inhibitor and microdissected into glomerular and tubular fragments. Total mRNA 
isolation from microdissected glomeruli and reverse transcription real-time PCR were 
performed as reported previously by Cohen and coworkers [106]. Pre-developed 
TaqMan reagents were used for human BiP (NM_005347.2), HYOU (NM_006389.2) 
CHOP (NM_004083.4), as well as reference genes (Applied Biosystems). The 
expression of BiP, HYOU1 and CHOP was normalized to the mean of three reference 
genes: GAPDH, 18 rRNA and synaptopodin. The mRNA expression was analyzed by 
standard curve quantification [107].  
2.11 Incorporation of palmitic acid into diglycerides (DAGs) and 
triglycerides (TGs) and ß-oxidation [108] 
Pretreatment was carried out in complete medium for 14 hours. The experiment was 
performed in serum-free medium supplemented with 0.5% FFA-free BSA containing 
200 ?M palmitic acid or the combination of palmitic and oleic acid (100 ?M each) in 
the presence of 0.5 ?Ci/ml [3H]-palmitic acid. 
2.11.1 DAG and TG analysis 
At the particular time points the cells were washed three times with cold PBS and 
scraped in a volume of 120 ?l PBS. To extract total lipids the lysates were transferred 
to 500 ?l chloroform/methanol/5N HCl (2:1:0.05, v/v), rotated for 5 min and 
centrifuged at 350xg for 5 min. The organic phase was dried under N2 and redissolved 
in 30 ?l of chloroform. 5 ?l were applied to measure radioactivity of the total lipid 
fraction and 20 ?l were loaded onto silica plates (20x20 cm; Sigma). Lipid fractions 
were separated by unidimensional thin layer chromatography in n-Hexane/diethyl 
ether/methanol (45:10:1, v/v). The lipid standards (Sigma) were visualized by 
spraying with KMnO4 and subsequent drying and heating with a Bunsen burner. The 
spots corresponding to the adequate markers were scraped into scintillation vials and 
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after addition of 150 ?l methanol and 2 ml of scintillation buffer radioactivity was 
measured. Values of DAGs and TGs were normalized to total lipid. 
2.11.2 ß-oxidation determination 
At the particular time points the supernatant (1 ml) was transferred to 5 ml of 
chloroform/methanol/5N HCl (2:1:0.05, v/v), rotated for 5 min and spun down at 
350xg for 5 min. 500 ?l of the aqueous phase was added to 2 ml of scintillation buffer 
before measuring radioactivity. Values of ß-oxidation were normalized either to total 
protein or total lipid. 
2.12 Statistical anlaysis 
Data are expressed as means and SD. Significance of differences was calculated with 
a two-sided, unpaired t-test. For the real-time RT-PCR data of mRNA expression in 
renal biopsies statistical analysis was performed using Kruskal-Wallis and Mann-
Withney U tests. 
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3. RESULTS 
3.1 Regulation of podocyte survival and endoplasmic reticulum 
stress by fatty acids [109] 
3.1.1 Palmitic acid induces apoptosis in podocytes 
The saturated palmitic acid is inducing cell death in several cell types [53, 57, 110]. In 
a first experiment podocytes were exposed to 500 ?M palmitic acid complexed to 
BSA for 10, 24, 34 and 48 hours and stained with annexin V and PI (Fig. 3a). 
 
 
Figure 3: Time-dependent induction of apoptosis and necrosis by palmitic acid. a) 
Representative flow cytometry results for podocytes treated with 500 ?M palmitic acid or 
BSA for 10, 24, 34 and 48 hours and stained for annexin V and PI. b,c) Bar graphs represent 
mean fold-increase ± SD of apoptotic (annexin V-positive/PI-negative) and necrotic (annexin 
V-positive/PI-positive) podocytes, respectively. BSA controls were set to 1. d) Bar graph 
represent the number of cells recovered from culture dishes to analyze by flow cytometry. 
  20 
Decreasing number of cells reflect the accumulation of necrotic cell debris that could not be 
recovered for flow cytometry. (n = 3, * p = 0.05, ** p < 0.05, *** p < 0.01). 
 
Fatty acid free BSA was used as a control. Annexin V single positive cells were 
considered as (early) apoptotic and annexin V and PI double positive cells as (late 
apoptotic and) necrotic cells. Cell death of podocytes, both apoptosis and necrosis, 
increased over time and became apparent after 24 hours. After 48 hours, a 2.5 to 3-
fold increase of apoptotic and necrotic podocytes was observed (p < 0.01, Figs. 3b, c). 
Of note, the increase of annexin V/PI double positive late apoptotic/necrotic was 
underestimated by flow cytometry as more floating cellular debris was formed in the 
supernatants of cell pellets used for flow experiments over time. This was reflected in 
a decreased total number of cells recovered in cell pellets after 34 and 48 hours (p < 
0.05; Fig. 3d). 
500 ?M of palmitic acid is a high free fatty acid concentration even under diabetic 
conditions. Therefore, apoptosis and necrosis was additionally examined at lower 
concentrations (125, 250 ?M) of palmitic acid (Fig. 4).  
 
 
Figure 4: Palmitic acid induces apoptosis and necrosis in a dose-dependent manner. a) 
Representative flow cytometry results for podocytes exposed to 125, 250 and 500 ?M 
palmitic acid or BSA (at concentration equivalent to cells treated with 500 ?M palmitic acid 
complexed to BSA) for 38 hours. The abscissa and ordinate represent the fluorescence 
intensity of annexin V and PI, respectively. b) Quantitative analysis of palmitic acid-induced 
cell death. Bar graph represents the mean percentages ± SD apoptotic and necrotic podocytes 
(n = 3; * p < 0.05, ** p < 0.01). 
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After 24 hours of treatment no toxic effect was visible at 125 and 250 ?M (data not 
shown). Palmitic acid-induced cell death was dose-dependently increased after 38 
hours. In BSA control, 5.2 ± 0.1% of podocytes were apoptotic and 5.9 ± 0.9% were 
necrotic. Palmitic acid significantly increased apoptosis at 250 (9.1 ± 0.9%, p < 0.01; 
Fig. 4b) and 500 ?M (14.0 ± 0.2%, p < 0.01; Fig. 4b). Similar findings were observed 
for necrosis (at 500 ?M, 17.3 ± 1.2, p < 0.01; Fig. 4b). Furthermore necrotic cells 
were already increased at 125 ?M (Fig. 4b). 
To confirm the effect of palmitic acid on apoptosis and necrosis with a second 
independent approach caspase 3 cleavage and mitochondrial cytochrome c release 
were examined by Western blotting. As caspase 3 activation occurs before 
externalization [111] of phosphatidylserine podocytes were treated with palmitic acid 
for 1 and 16 hours. Staurosporine, a general kinase inhibitor and a strong inducer of 
apoptosis, was used as a positive control. Cleaved caspase 3 was detected in 
staurosporine-treated podocytes after 1 hour. In palmitic acid-treated podocytes the 
effect was visible after 16 hours (Fig. 5a). Consistent with the flow cytometry data 
activation of caspase 3 was also observed at lower concentrations of palmitic acid 
(Fig. 5b). In addition, mitochondrial cytochrome c was released into the cytosol after 
exposure to palmitic acid (Fig. 5c). 
 
 
Figure 5: Palmitic acid activates caspase 3 and induces mitochondrial cytochrome c 
release. Western blot of activated, cleaved caspase 3 of podocytes exposed to staurosporine 
(0.25 ?M), BSA or palmitic acid. ß-actin was used as a control. a) Staurosporine and palmitic 
acid (500 ?M) caused strong activation of caspase 3 at 16 hours. No signal was detected after 
1 hour-treatment of palmitic acid. b) Dose-dependent cleavage of caspase 3 in podocytes 
exposed to 125, 250 or 500 ?M palmitic acid for 16 hours. c) Western blot of cytosolic 
cytochrome c of podocytes exposed to palmitic acid (250 ?M) for 16 hours. ß-actin served as 
a loading control. 
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3.1.2 Palmitic acid induces ER-stress 
The toxicity of palmitic acid has been attributed to involve the induction of ER-stress 
[52, 54, 56, 61, 62]. Therefore, the effect of palmitic acid on protein levels of BiP, an 
ER chaperone that is upregulated during ER-stress, and CHOP, a proapoptotic 
transcription factor that is typically upregulated in severe and prolonged ER-stress 
was studied [112]. 500 ?M palmitic acid led to a 6-fold (p < 0.01) upregulation of BiP 
at 24 hours (Fig. 6a). Analogous to apoptosis and necrosis BiP was also induced at 
lower concentrations (data not shown). Similarly, CHOP levels were increased 9 
times (p < 0.01) in podocytes treated for 24 hours with 500 ?M palmitic acid (Fig. 
6b). In addition, CHOP induction was dose- and time-dependent and it occurred as 
early as 6 hours (Fig. 6c). Other known apoptotic stimuli as high glucose [25], TGF-ß 
[36] and staurosporine did not induce CHOP (Fig. 6e). However, high glucose might 
enhance the effect of palmitic acid. Interestingly, TGF-ß (5 ng/ml) alone or in 
combination with high glucose induced BiP. 
XBP-1 is involved in the transcriptional activation of CHOP in ER-stress, but only the 
spliced form of XBP-1 (sXBP-1) has transcriptional activity [113]. Therefore, RT-
PCR had been used to amplify fragments of XBP-1 representing both the unspliced 
(uXBP-1) and the spliced (sXBP-1) forms of XBP-1 mRNA. Palmitic acid and 
tunicamycin (Tn), an established inducer of ER-stress, strongly induced sXBP-1 and 
an additional slower migrating band (Fig. 6d). The slowly migrating band represents a 
hybrid form of uXBP-1 and sXBP-1 (hXBP-1), which can form during annealing in 
the last PCR step [114]. XBP-1 splicing was increased as early as 4 hours after 
exposure to palmitic acid (data not shown), implying a potential role of XBP-1 
splicing in transcriptional activation of CHOP [112]. 
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Figure 6: Palmitic acid induces ER-stress: the chaperone BiP, the proapoptotic 
trancription factor CHOP and splicing of XBP-1 mRNA. a) Palmitic acid-induced 
upregulation of BiP (top) and quantitative analysis of BiP levels normalized to ß-actin. BSA 
control was set to 100% (n = 4; * p < 0.01). b) Palmitic acid-induced upregulation of CHOP 
(top) and quantitative analysis of CHOP levels normalized to ß-actin. BSA control was set to 
100% (n = 4; * p < 0.01). c) Time- and dose-dependent induction of CHOP in podocytes 
exposed to 125, 250 or 500 ?M palmitic acid for either 6 or 24 hours. d) RT-PCR of XBP-1 
after exposure of 500 ?M palmitic acid for 12 hours. In BSA-treated controls the unspliced 
fragment (u) was predominant whereas treatment with palmitic acid and tunicamycin (5 
?g/ml) augmented the spliced (s) and the hybrid (h) form. e) BiP and CHOP expression after 
24 hours of exposure. Lane 1, control BSA and 5 mM glucose (LG); lane 2, BSA control, LG 
and 17 mM Mannitol (M); lane 3, BSA control and 22 mM glucose (HG); lane 4, 500 ?M 
palmitic acid and LG; lane 5, 500 ?M palmitic acid and HG; lane 6, TGF-ß (5 ng/ml) and 
HG; lane 7, TGF-ß and LG; lane 8, 0.25 ?M staurosporine (stauro). ß-actin was used as a 
control. 
3.1.3 CHOP silencing attenuates palmitic acid-induced podocyte death 
As shown before, the proapoptotic transcription factor CHOP is markedly induced by 
palmitic acid treatment and levels are already elevated at early time points. To test 
whether CHOP is mechanistically involved in palmitic acid-induced cell death CHOP 
knockdown podocytes were generated. CHOP silencing was performed by lentivirus 
transduction using CHOP-specific shRNA and a scrambled sequence was used as a 
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control. Knockdown efficiency was examined by Western immunoblotting of whole 
cell lysates of podocytes treated with tunicamycin for 24 hours. CHOP levels were 
reduced by 88 ± 10% (p < 0.001; Fig. 7a, b). Surprisingly, BiP levels were also 
significantly decreased (44 ± 1%, p < 0.01; Fig. 7a, b). A similar picture was observed 
in podocytes treated with 500 ?M palmitic acid (Fig. 7c). 
 
 
Figure 7: CHOP-silencing protects against palmitic acid-induced cell death. a,b) Gene-
silencing of CHOP suppresses tunicamycin-induced upregulation of CHOP and BiP. Bar 
graphs (b) show the relative expression of CHOP ± SD. A scrambled shRNA was used as a 
control and set to 100%. ß-actin was used to normalize (n = 3, * p < 0.01, ** p < 0.001). c) 
CHOP shRNA suppresses palmitic acid-induced upregulation of CHOP and BiP. d-f) Gene-
silencing of CHOP blocks palmitic acid-induced apoptosis (200 ?M) after 38 hours but not 
necrosis. Bar graphs represent mean fold-increase ± SD of apoptotic (d), necrotic (e), and 
apoptotic + necrotic (f) cells. BSA controls were set to 1 (n = 3). 
 
In a next step, the effect of CHOP silencing on palmitic acid-induced apoptosis and 
necrosis was examined. As 500 ?M is a high concentration and a protective effect of 
CHOP knockdown might not become visible the experiments were performed with 
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200 ?M palmitic acid for 48 hours. Podocytes either transduced with CHOP-shRNA 
or scrambled-shRNA were treated with palmitic acid or BSA and stained with 
annexin V and PI. Absolute numbers of apoptotic and necrotic cells were slightly 
increased in CHOP-silenced podocytes compared to control (data not shown). 
Although, the relative fold-increase of apoptosis (the ratio palmitic acid to BSA 
control) was significantly reduced in CHOP-silenced cells (1.7 ± 0.2-fold) compared 
to control (2.4 ± 0.2-fold; Fig. 7d). No significant reduction was observed for necrosis 
(Fig. 7e). 
 
To verify the essential role of CHOP in inducing palmitic acid-induced podocyte 
death the experiments have been repeated with a second set of shRNA sequences (in 
Methods signed with (2)). Knockdown of CHOP was again efficient in podocytes 
treated with palmitic acid and tunicamycin but BiP levels remained unaffected (Fig. 
8a). Absolute numbers of apoptosis and necrosis were lower in CHOP-silenced cells 
treated with BSA (5.1 ± 1.0% and 5.8 ± 1.1%) compared to controls (8.8 ± 0.7% and 
8.5 ± 0.3%; Fig. 8b). Furthermore, apoptosis and necrosis were strongly prevented in 
palmitic acid-treated CHOP-silenced cells: 7.7 ± 0.6% vs. 21.8 ± 3.2% apoptotic cells 
and 7.6 ± 1.0% vs. 13.8 ± 0.8% necrotic cells (Fig. 8b). The effect is also highlighted 
in the significant reduction of the relative fold-increase in CHOP-silenced podocytes 
(Fig. 8c, d). Overall, the results of both CHOP-shRNA sequences indicate a crucial 
involvement of CHOP in mediating palmitic acid-induced cell death. 
 
  26 
 
Figure 8: Gene-silencing of CHOP with a second shRNA sequence. a) CHOP shRNA 
suppresses tunicamycin- and palmitic acid-induced upregulation of CHOP. However, BiP 
levels remain unchanged. b-d) Gene-silencing of CHOP prevents palmitic acid-induced cell 
death. A scrambled sequence served as a control. b) Bar graphs show mean percentages ± SD 
of apoptotic and necrotic cells (n = 3; p < 0.05). c,d) Bar graphs represent mean fold-increase 
± SD of apoptotic and necrotic cells, respectively. BSA controls were set to 1. 
3.1.4 Chemical chaperones do not protect podocytes from palmitic acid-
mediated death 
The previous results clearly point to an active contribution of ER-stress in palmitic 
acid-induced podocyte apoptosis and necrosis. Treatment with small molecules, 
classified as chemical chaperones have been reported to enhance ER folding [115]. 
Although the mechanisms of action of these compounds are not completely 
understood they have been classified as such due to their ability to protect cells from 
ER-stress and to facilitate protein folding [116, 117]. Two of these molecules, 4-
phenylbutyric acid (4-PBA) and tauroursodeoxycholic acid (TUDCA) have been 
demonstrated to reduce the induction of ER-stress in an obesity and type II diabetes 
mouse model [118]. To examine if chemical chaperones can reduce susceptibility 
towards palmitic acid-induced cell death, podocytes were treated with 4-PBA and 
TUDCA. 4-PBA worsened the effect of palmitic acid even at low concentrations (data 
not shown). On the other side TUDCA was not toxic itself but also had no clear 
beneficial effect on palmitic acid-induced apoptosis (Fig. 9; 0.5 mM TUDCA, p = 
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0.19). Palmitic acid-mediated ER-stress in podocytes might not be triggered by an 
accumulation of misfolded proteins but rather by impaired ER membrane integrity 
and ER-to-Golgi protein trafficking [87, 119]. 
 
 
Figure 9: The chemical chaperone TUDCA has no protective effect on palmitic acid-
induced cell death. Podocytes were pretreated with 0.25, 0.5, 1 and 5 mM TUDCA for 1 hour 
and incubated with 200 ?M palmitic acid for 48 hours. Bar graphs show mean percentages ± 
SD of apoptotic and necrotic cells (n = 3). 
3.1.5 Monounsaturated fatty acids prevent the induction of ER-stress and 
block palmitic acid-induced podocyte death 
Unlike saturated fatty acids (SFAs) monounsaturated fatty acids (MUFAs) as 
palmitoleic and oleic acid show no toxic effects on several cell types and furthermore 
they could rescue cells from palmitic acid-induced cell death and ER-stress [92, 120]. 
Therefore, podocytes exposed to 500 ?M palmitic acid were coincubated with either 
500 ?M palmitoleic or oleic acid. Induction of apoptosis and necrosis was analyzed 
after 38 hours. Both, palmitoleic and oleic acid could prevent podocyte death caused 
by palmitic acid (Fig. 10a, c). In line with this observation palmitoleic and oleic 
reduced the induction of CHOP and BiP (Fig. 10b, d). 
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Figure 10: Palmitoleic and oleic acid prevent podocytes from palmitic acid-induced cell 
death and attenuate CHOP induction. a,c) palmitoleic and oleic acid block palmitic acid-
induced cell death after 38 hours. Bar graphs represent mean fold-increase ± SD of apoptotic 
and necrotic cells. BSA controls were set to 1 (n = 3; * p < 0.05 ** p < 0.01 compared with 
palmitic acid). b,d) palmitoleic and oleic acid block palmitic acid-induced upregulation of BiP 
and CHOP after 16 and 24 hours. ß-actin was applied as a loading control. 
3.1.6 Glomerular mRNA levels of BiP are induced in patients with DN 
As shown before elevated SFA levels lead to ER-stress in podocytes in vitro. In 
addition induction of ER-stress has been observed in two rodent DN models [121, 
122]. To evaluate an involvement of ER-stress in DN mRNA levels of the ER-stress 
markers BiP, CHOP and hypoxia-upregulated protein 1 (HYOU1) were quantified in 
glomerular extracts of patients with DN. They were compared to healthy controls and 
patients with minimal change disease (MCD). Consistent to the in vitro data the 
chaperone BiP was significantly upregulated in DN patients (Fig. 11). HYOU1 levels 
showed increased tendency but the data were not significant (Fig. 11). Interestingly, 
the proapoptotic factor CHOP was significantly down compared to both healthy 
controls and MCD patients (Fig. 11). These findings in one hand confirm a 
participation of ER-stress as BiP was up but on the other hand the downregulation of 
CHOP is opposing the in vitro data. It may be explained by the possibility that 
apoptotic podocytes detach and are not included in the analysis. 
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Figure 11: In DN patients mRNA expression levels of BiP are increased and CHOP 
levels are downregulated. mRNA levels of BiP, HYOU1 and CHOP were quantified in 
microdissected glomeruli from controls (CON; n = 6), patients with MCD (n = 12) and 
patienst with established DN (n = 8). The graphs show expression ratios of each gene 
normalized to three reference genes (18S rRNA, hGAPDH and synaptopodin). 
 
3.2 Role of Steroly-CoA Desaturases in palmitic acid-induced ER-
stress and cell death in podocytes (Manuscript in preparation) 
As MUFAs such as palmitoleic acid or oleic acid can reduce the induction of ER-
stress and completely protect podocytes from palmitic acid-induced cell death, I 
explored in a next step whether stimulation of podocyte autonomous fatty acid 
desaturases can protect podocytes from palmitic acid-induced cell death. 
Stearoyl-CoA desaturases (SCDs) catalyze the ?9-desaturation of SFA. Four SCD 
isoforms have been identified in mice [123-125]. In the current literature, SCD-1 and 
SCD-2 are ubiquitously expressed whereas SCD-3 expression is restricted to the skin, 
preputial gland and harderian gland and SCD-4 to the heart [125, 126]. The 
predominant isoform in most tissues including the kidney is SCD-1 [126] and SCD-1 
is positively regulated by liver X receptor (LXR) binding to an LXR response element 
in the SCD-1 promoter [127] and by LXR-mediated stearoyl regulatory-element 
binding protein 1c (SREBP1c) transcription [128]. 
3.2.1 TO901317 (TO) ameliorates survival of palmitic acid-treated podocytes 
To investigate the potentially beneficial action of SCDs on palmitic acid-induced 
lipotoxicity in podocytes it has been taken advantage of TO901317 (TO), an LXR 
agonist [129], which is known to induce SCD-1. Figure 12a shows that TO-treatment 
of podocytes for 14 hours led to a 2-3-fold increase in SCD-1 levels. To test the effect 
of TO on cell viability, podocytes were pretreated with 1?M TO for 14 hours and 
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subsequently incubated with 200 ?M palmitic acid for 48 hours. Incubation with TO 
reduced apoptosis by 38 ± 6% and necrosis by 30 ± 8% (Fig. 12b). 
 
 
Figure 12: TO induces SCD-1 and ameliorates survival of palmitic acid-treated 
podocytes. a) 14 hours treatment with TO upregulates protein levels of SCD-1. ß-actin was 
used as a control. Bar graph represents relative expression ± SD of SCD-1. Vehicle (DMSO) 
treatment was set to 100% (n = 3, * p < 0.05). b) 14 hours pretreatment with TO protects 
podocytes from palmitic acid-induced death. Bar graphs represent mean percentages ± SD of 
apoptotic and necrotic cells (n = 3, * p < 0.01).  
3.2.2 In podocytes SCD-2 is the predominant SCD isoform and TO strongly 
induces SCD-1 and SCD-2 
To investigate whether the protective effect of TO on palmitic acid-induced podocyte 
death may be related to the induction of SCDs the expression pattern of the various 
isoforms was evaluated in whole kidney lysates and podocytes. Real-time RT-PCR 
revealed that all four isoforms are expressed in the kidney (Fig. 13a) as well as in 
podocytes (Fig. 13b). Consistent with data from others [126] the most abundant 
isoform in the kidney is SCD-1 followed by SCD-2 (25% of SCD-1). Compared to 
SCD-1, SCD-3 (3%) and SCD-4 (< 1%) showed low expression levels in kidney 
lysates (Fig. 13a). Contrariwise, in podocytes SCD-2 was identified as the 
predominant isoform with 8-fold higher mRNA levels than SCD-1 (Fig. 13b). Similar 
to the expression in whole kidney lysates, expression levels of SCD-3 (22% of SCD-
1), and SCD-4 (< 1%) were also low in podocytes  (Fig. 13b). Next, the effect of TO 
on SCD mRNA expression has been examined in podocytes. Comparable to the effect 
of TO on SCD-1 protein levels (Fig. 12a), TO strongly induced SCD-1 (2.5 ± 0.4-
fold, p < 0.01), and to an even higher extent SCD-2 mRNA levels (5.0 ± 0.9-fold, p < 
0.01; Fig. 13c). Contrariwise, SCD-3 and SCD-4 mRNA levels were not significantly 
increased by TO (Fig. 13c). 
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Figure 13: The expression pattern of SCD isoforms in the whole kidney differs from 
podocytes and TO strongly upregulates SCD-1 and SCD-2 in podocytes. a,b) SCD-1 is 
predominant in the kidney whereas in podocytes SCD-2 shows highest expression levels. 
Compared to SCD-1 and SCD-2 mRNA levels of SCD-3 and SCD-4 are low. Bar graphs 
represent relative expression ± SD in the kidney (a) and in podocytes (b); each isoform was 
normalized to GAPDH and SCD-1 expression was set to 100%. c) Real-time RT-PCR 
analysis of SCD-1, SCD-2, SCD-3 and SCD-4 at 14 hours of TO-treatment. Bar graph 
represents fold induction ± SD of each isoform normalized to GAPDH. Vehicle (DMSO) 
treatment was set to 1 (n = 3, * p < 0.01). 
3.2.3 Gene-silencing of SCD-2 and SCD-1 reverts the protective effect of TO on 
palmitic acid-induced podocyte death 
To investigate the role of desaturases in the protective action of TO, SCD-2 
knockdown podocytes were generated as SCD-2 is the predominant isoform in 
podocytes and as SCD-2 is strongly induced by TO (Fig. 13a, c). SCD-2 knockdown 
podocytes were generated by lentiviral infection using a SCD-2-specific shRNA. A 
scrambled shRNA was used as a control. By RT-PCR, a marked suppression of SCD-
2 expression (Fig. 14a) was observed in podocytes transduced with the SCD-2 
silencing shRNA. To assess the effect of TO on podocytes deficient in SCD-2, 
podocytes were either pretreated with TO or vehicle for 14 hours before incubation 
with 200 ?M palmitic acid for 48 hours. SCD-2 silenced podocytes showed increased 
overall apoptosis and necrosis (data not shown) but SCD-2 silencing did not affect the 
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protective effect of TO on palmitic acid-treated podocytes (Fig. 14b-d). As shown in 
Figure 14, the protection of TO was not reduced in SCD-2-silenced podocytes, i.e. TO 
blocked palmitic acid-induced apoptosis to a similar degree in controls, and SCD-2 
knockdown cells, by 26 ± 10%, and by 29 ± 7%, respectively (Fig. 14b). Similar 
findings were observed for necrosis as well as apoptosis and necrosis combined (Fig. 
14c, d). 
 
 
Figure 14: SCD-2 silencing does not affect the protective effect of TO on palmitic acid-
induced podocyte death. a) SCD-1 and SCD-2 shRNA suppress the TO-mediated 
upregulation of SCD-1 and SCD-2 as analyzed by RT-PCR. ß-actin served as a control. b-d) 
Podocytes were pretreated with 1 ?M TO for 14 hours and incubated with 200 ?M palmitic 
acid for 48 hours. Bar graphs represent mean fold-increase ± SD of apoptosis (a), necrosis (b) 
and apoptosis+necrosis (c). Vehicle (DMSO) control was set to 1 (n = 3). 
 
As SCD-1 might compensate for SCD-2 SCD-1/SCD-2 double-deficient podocytes 
were generated. As for SCD-2, efficiency of SCD-1 knockdown was assessed by RT-
PCR (Fig. 14a). SCD-1/SCD-2 double-deficient podocytes were highly susceptible to 
palmitic acid-induced cell death and apoptotic cells increased from 8.5 ± 1.0% to 21.6 
± 0.9% in palmitic acid-treated controls and SCD-1/SCD-2 double-deficient cells, 
respectively (Fig. 15a), and most importantly the protective effect of TO was largely 
abrogated (Fig. 15a). In SCD-1/SCD-2 double-deficient podocytes the protective 
effect of TO on apoptosis was reduced from 40.3 ± 4.0% in control cells to 11.1 ± 
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7.7% (p < 0.01) in SCD-1/SCD-2 double-silenced cells (Fig. 15b). Similarly, the 
protective effect of TO on apoptosis and necrosis combined was reduced from 30.6 ± 
1.1% in control cells to 11.6 ± 7.9% (p < 0.05) in SCD-1/SCD-2 double-silenced cells 
(Fig. 15d) whereas no significant impact was seen for necrosis (Fig. 15c). Together, 
these data indicate that SCD-1 and SCD-2 induction are mainly responsible for the 
protective effect of TO. Furthermore, SCD-1 and SCD-2 are presumably 
compensating for each other as a single-knockdown of SCD-1 (data not shown) and 
SCD-2 (Fig. 14) could not prevent the protective effect of TO on palmitic acid-
induced podocyte apoptosis. 
 
 
Figure 15: Combined silencing of SCD-1 and SCD-2 partially reverses the protective 
effect of TO on palmitic acid-induced apoptosis. Podocytes were pretreated with 1 ?M TO for 
14 hours and incubated with 200 ?M palmitic acid for 48 hours. a) Bar graph represents mean 
percentages ± SD of apoptotic and necrotic cells. b-d) Bar graphs represent mean fold-
increase ± SD of apoptosis (b), necrosis (c), and apoptosis + necrosis (d). Vehicle-treated 
(DMSO) control was set to 1. n = 3; * p < 0.05, ** p < 0.01. 
3.2.4 Genetic overexpression of SCD-1 partially protects from palmitic acid-
induced apoptosis 
To further confirm the important role of SCDs on palmitic acid-induced apoptosis of 
podocytes a genetic approach, again by lentiviral transduction, was used by 
overexpressing SCD-1 in podocytes. Overexpression of SCD-1 was confirmed by 
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Western immunoblotting (Fig. 16a). Initially, GFP-overexpressing cells showed 
higher basal cell death that was associated with higher occurrence of ER-stress (data 
not shown). To overcome this problem podocyte transduction was carried out using 
lower virus titers and the cells were left to recover from ER-stress for 5 days before 
entering the experiment as BiP and CHOP levels were decreasing over time (data not 
shown). Treatment with BSA control for 48 hours showed comparable basal apoptosis 
and necrosis levels: 2.9 ± 0.2% apoptotic and 5.1 ± 0.9% necrotic cells in SCD-1 
overexpressing cells versus 3.8 ± 0.4% apoptotic and 4.3 ± 0.7% necrotic cells in 
GFP-overexpressing cells (Fig. 16b). High levels of SCD-1 significantly prevented 
palmitic acid-induced apoptotic (7.0 ± 0.3% vs. 10.3 ± 0.7%, p < 0.01; Fig. 16b) and 
necrotic events (5.7 ± 0.4% vs. 7.3 ± 0.5%, p < 0.05; Fig. 16b). In Figure 16c and 16d 
the results of five independent experiments are pooled. Compared to GFP 
overexpression (set to 1), SCD-1 overexpression reduced the increase of apoptosis 
and necrosis after exposure to palmitic acid compared to podocytes incubated with 
BSA (control) by 16 ± 9% (p < 0.0001) and 12 ± 18% (p < 0.05), respectively (Fig. 
16c, d). These data indicate that genetic overexpression of SCD-1 protects podocytes 
from palmitic acid-induced apoptosis, which is in complete accordance with the SCD-
1 and SCD-2 dependent protective effect of TO (Fig. 15a-d). 
 
Figure 16: Overexpressing SCD-1 moderately protects from palmitic acid-induced 
apoptosis and necrosis. a) Western blot analysis of SCD-1 levels in GFP- or SCD-1 
overexpressing podocytes. ß-actin served as a loading control. b-d) SCD-1 overexpression 
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blocks palmitic acid-induced apoptosis and necrosis in podocytes. b) Bar graphs show mean 
percentages ± SD of apoptotic and necrotic cells after exposure to 200 ?M palmitic acid for 
48 h (representative experiment; n = 3, * p < 0.05, ** p < 0.01). c,d) Bar graphs represent the 
relative effect ± SD of palmitic acid on apoptosis (c) and necrosis (d) in GFP- or SCD-1 
overexpressing podocytes. GFP control was set to 1 (5 experiments pooled; n = 13, * p < 
0.05, ** p < 0.0001). 
3.2.5 MUFAs and TO shift palmitic acid into triglycerides (TGs) and MUFAs 
induce fatty acid ß-oxidation 
The mechanisms how MUFAs protect from SFA-mediated lipotoxicity are not 
completely understood. The protective effect of MUFAs is thought to be related to 
their stimulatory effect on fatty acid ß-oxidation and on their ability to shift fatty acids 
into triglycerides (TGs) [50]. Both pathways are thought to prevent from harmful SFA 
metabolites either by getting rid of SFAs (ß-oxidation) or by storing them away 
(TGs). 
 
Figure 17: Oleic acid and TO increase palmitic acid incorporation into the TG fraction 
but only oleic acid reduces palmitic acid containing DAG levels in palmitic acid-treated 
podocytes. Podocytes were incubated for 5 hours in serum-free medium containing 0.5% 
FFA-free BSA and supplemented with 200 ?M palmitic acid (± 1 ?M TO) or oleic and 
palmitic acid (100 ?M each) in the presence of 0.5 ?Ci/ml [3H]-palmitic acid. a-d) DAG and 
TG fractions were separated by thin layer chromatography and analyzed by a liquid 
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scintillation counter. a,b) Bar graphs represent the mean ratio of [
3
H]-palmitic acid-
incorporated TGs to DAGs ± SD (n = 9; * p < 0.001). c,d) Bar graphs represent the relative 
incorporation ± SD of [
3
H]-palmitic acid into DAGs (c) and TGs (d) normalized to total lipid 
(n = 9; * p < 0.01). Vehicle-treatment was set to 1.  
 
To investigate changes in lipid storage and fatty acid oxidation by MUFAs and TO 
tritium-labeled palmitic acid was used to trace incorporation of palmitic acid into 
diglycerides (DAGs) and TGs as well as to estimate levels of ?-oxidation of palmitic 
acid. Analysis of the TG to DAG ratio revealed a shift of palmitic acid towards TG in 
the presence of oleic acid and TO. As shown in Figure 17b, coincubation with oleic 
acid strongly shifted the ratio towards the TG fraction (2.8 ± 0.6-fold, p < 0.001). TO 
also increased the proportion of fatty acids derived from tritium-labeled palmitic acid 
incorporated in TGs in relation to DAGs but to a lower extent (1.3 ± 0.2-fold, p < 
0.001; Fig. 17a). Looking at the single fractions, the presence of oleic acid not only 
increased the radioactive-labeled TG fraction (Fig. 17d), but also markedly reduced 
the radioactive-labeled DAG fraction (53 ± 8% of control cells, Fig. 17c). 
Interestingly, the latter could not be seen for cells treated with TO, although TO 
significantly increased the proportion of fatty acids derived from tritium-labeled 
palmitic acid incorporated in TGs (Fig. 17c, d). Further, the effect of oleic acid on ?-
oxidation of palmitic acid has been investigated. Podocytes were incubated with 200 
?M palmitic acid along with 0.5 ?Ci/ml tritiated palmitic acid. In this assay the 
formation of [
3
H2O] is utilized as a read out of ß-oxidation of palmitic acid, and 
oxidation of palmitic acid is expressed as disintegrations per minute (DPM) 
normalized to the total protein of cell lysates. 5 hours cotreatment with oleic acid 
elevated ß-oxidation by 30-40% when compared to palmitic acid-treated podocytes 
(Fig. 18). In contrast, the presence of TO revealed no detectable change in palmitic 
acid ?-oxidation (Fig. 18). Together, these data indicate that oleic acid increases ß-
oxidation of palmitic acid in addition to shifting palmitic acid from DAGs to TGs. 
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Figure 18: Cotreatment with oleic acid but not TO increases palmitic acid ß-oxidation. 
Podocytes were incubated for 5 hours in serum-free medium containing 0.5% FFA-free BSA 
and supplemented with 200 ?M palmitic acid (± 1 ?M TO) or oleic and palmitic acid (100 
?M each) in the presence of 0.5 ?Ci/ml [3H]-palmitic acid. ß-oxidation was determined by 
counting [
3
H2O] as a product of ß-oxidation in the aquous phase of the incubation medium. 
Bar graph represents relative ß-oxidation ± SD normalized to total lipid (n = 9, * p < 0.001). 
Vehicle-treatment was set to 1. 
 
Taken together the LXR agonist TO partially protected podocytes from palmitic acid-
induced death. The effect might be explained to a large part by induced expression of 
SCD-1 and SCD-2 as combined gene silencing almost completely reversed the 
beneficial effect of TO, and SCD-1 overexpression moderately but significantly 
suppressed palmitic acid-induced podocyte apoptosis. Mechanistically, the increased 
incorporation of palmitic acid into TGs that has been observed by the combination 
with oleic acid, but also by the treatment of podocytes with TO is indicating a 
potential benefit of lipid storage. The higher ability of oleic acid to increase lipid 
storage by comparison to TO, and its additional effect on ß-oxidation might explain 
the stronger effect of oleic acid compared to TO. 
 
3.3 The role of cAMP levels on palmitic acid-induced apoptosis in 
podocytes 
The data described in part 3.1 are indicating that ER-stress has a crucial role in 
palmitic acid-induced podocyte death. In order to investigate how podocytes might be 
protected from palmitic acid-mediated lipotoxicity, molecular pathways have been 
  38 
investigated that are preventing ER-stress or are inducing prosurvival pathways of the 
UPR response. The adenylate cyclase (AC) agonist forskolin [130] has been shown to 
ameliorate survival of palmitic acid-treated pancreatic ß cells [131]. The effect of 
forskolin has been attributed basically to the upregulation of the ER chaperone BiP 
and the transcription factor JunB, which has been shown to be antiapoptotic in 
pancreatic ß cells exposed to chemical ER-stressors [132]. 
3.3.1 Forskolin protects podocytes from palmitic acid-induced ER-stress and 
death by increasing cAMP levels 
To examine the effect of forskolin on palmitic acid-induced death in podocytes, cells 
were pretreated with forskolin for 14 hours before incubation with 200 ?M palmitic 
acid for 48 hours. Analysis of apoptosis and necrosis revealed that palmitic acid-
induced death was lower in forskolin-treated podocytes (Fig. 19a). Apoptosis was 
blocked by 40-60% (p < 0.01) and necrosis by 24% (p < 0.05; Fig. 19a and Fig. 20a). 
Forskolin is an agonist of AC that is converting ATP into cyclic AMP (cAMP). 
Therefore, the direct effect of elevated cAMP levels was tested on palmitic acid-
induced cell death using 8-Br-cAMP, which is a cell permeable cAMP analogon with 
a higher resistance to phosphodiesterases. Indeed, pretreatment with 8-Br-cAMP of 
podocytes treated with 200 ?M palmitic acid for 48 hours protected from apoptosis 
and necrosis to a similar extent as forskolin (Fig. 20a), i.e 100 respectively 200 ?M of 
8-Br-cAMP suppressed apoptosis by 54 ± 5% (p < 0.001) and 63 ± 6% (p < 0.001). 
To examine if reduced induction of apoptosis and necrosis is due to higher levels of 
the ER chaperone BiP whole cell lysates were analyzed by Western blot. 
Contradictory to pancreatic ß cells, forskolin reduced the induction of BiP in 
podocytes treated with palmitic acid for 24 hours (Fig. 19b). Even at early time 
points, 4 and 9 hours, BiP expression was lower (data not shown). In addition, CHOP 
levels were significantly lower (Fig. 19b). Thus, consistent with the effect on 
apoptosis and necrosis, forskolin is reducing palmitic acid-induced CHOP induction 
in podocytes, which may indicate that forskolin is directly influencing ER-stress. 
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Figure 19: Forskolin protects from palmitic acid-induced apoptosis and reduces the 
induction of ER-stress. a) 14 hours pretreatment of forskolin decreases palmitic acid-induced 
cell death. Bar graph represents mean percentages ± SD of apoptotic and necrotic cells (n = 3, 
* p < 0.05, ** p < 0.01). b) Forskolin-treatment reduces palmitic acid-induced upregulation of 
BiP and CHOP at 24 hours. Bar graph shows relative CHOP expression, vehicle (DMSO) 
control was set to 100% (* p < 0.05). 
3.3.2 8-CPT-2Me-cAMP is less potent than 8-Br-cAMP in preventing palmitic 
acid-induced podocyte death 
Besides cAMP-gated ion channels the effects of cAMP are attributed to activation of 
protein kinase A (PKA) and Epac (exchange protein directly activated by cAMP) 
[133]. Enserink and colleagues [134] generated a cAMP analogon, 8-CPT-2Me-
cAMP, that is reported to activate Epac specifically. In order to discriminate between 
both pathways the effect of 8-CPT-2Me-cAMP was compared to 8-Br-cAMP (Fig. 
20b). As already shown above 200 ?M 8-Br-cAMP that is activating PKA and Epac 
suppressed apoptosis by 57 ± 6% (p < 0.001) and necrosis by 24 ± 7% (p < 0.05). By 
contrast 8-CPT-2Me-cAMP showed a moderate but not significant protection 
compared to palmitic acid-treated controls: 15 ± 11% (p < 0.08) less apoptotic and 13 
± 7% (p < 0.1) less necrotic cells (Fig. 20b). Together these results indicate that the 
effect of forskolin and thereby cAMP on palmitic acid-induced apoptosis and necrosis 
may mainly involve PKA. 
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Figure 20: The positive effect of forskolin on palmitic acid-induced apoptosis is caused 
by elevating levels of cAMP. a) 14 hours pretreatment of 8-Br-cAMP (100 and 200 ?M) 
mimicks the effect of forskolin. b) 8-CPT-2Me-cAMP (200 ?M) is less potent than 8-Br-
cAMP. 8-CPT-2Me-cAMP tends to slightly suppress (not significant) cell death. Bar graphs 
represent mean percentages ± SD of apoptotic and necrotic cells exposed to 200 ?M palmitic 
acid for 48 hours. (n = 3; * p < 0.05, ** p < 0.01, *** p < 0.001). 
3.3.3 H89 partially reverts the protective effect of forskolin on palmitic acid- 
induced apoptosis but is itself enhancing the effect of palmitic acid 
To further investigate if the protective effect of forskolin on palmitic acid-induced 
podocyte death is mediated by PKA signaling the effect of forskolin had been studied 
in the presence of the PKA inhibitor H89. Podocytes were pretreated with 1 ?M 
forskolin for 14 hours in the presence or absence of various dosages of H89 before 
treatment with 200 ?M palmitic acid for 48 hours (Fig. 21). H89 partially reverted the 
favorable result of forskolin in a dose-dependent manner. However, 10 ?M H89 was 
itself aggravating the effect of palmitic acid-induced apoptosis and necrosis (Fig. 21). 
Thus, even though H89 is reducing the beneficial effect of forskolin on palmitic acid-
induced cell death, the H89 experiment cannot firmly establish that the favorable 
effect of forskolin involves PKA signaling as H89 itself had a deleterious effect on 
palmitic acid-treated podocytes. Nevertheless, PKA signaling seems to exhibit 
prosurvival effects in palmitic acid-induced podocyte death. 
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Figure 21: H89 is partially reverting the beneficial effect of forskolin on palmitic acid-
induced apoptosis and necrosis but is enhancing itself the effect of palmitic acid. Podocytes 
were pretreated with forskolin in the absence or presence of H89 and subsequently treated 
with 200 ?M palmitic acid for 48 hours. Bar graphs represent mean percentages ± SD of 
apoptotic and necrotic cells (n = 2). 
3.3.4 Forskolin is activating the transcription factor CREB 
The most characterized signal transduction cascade of cAMP downstream of PKA 
involves the transcription factor cAMP response element binding protein (CREB). 
Phosphorylation by PKA leads to dimerization of CREB and transcriptional 
regulation of various proteins [135, 136]. Activation of CREB was confirmed in 
podocytes treated with forskolin for 0.5, 1, 2 and 24 hours. P-CREB formation peaked 
at 0.5 hours and decreased over time with no detectable signal after 24 hours (Fig. 
22a). Since signal transduction is apparently rapid pretreatment with forskolin was 
reduced to 2 hours and removed during the following treatment with 200 ?M palmitic 
acid. After 48 hours podocyte survival was again ameliorated by 31 ± 13% less 
apoptotic and by 24 ± 6% less necrotic events (Fig. 22b). 
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Figure 22: Forskolin activates CREB in podocytes and induces its downstream target 
Bcl-2 at an early time point. a) Phosphorylation of CREB is an early event in forskolin-
treatment and decreases over time. Levels of Bcl-2 are induced after 30 min but are 
comparable to DMSO control treatment at later timepoints. Total CREB and ß-actin served as 
loading controls. b) In addition, 2 hours preincubation of forskolin and removal during 
palmitic acid exposure is enough to significantly block palmitic acid-induced cell death. Bar 
graphs represent mean percentages ± SD of apoptotic and necrotic cells (n = 3; * p < 0.05, ** 
p < 0.01). 
 
To further examine a potential contribution of CREB, a dominant negative form 
(ACREB) was overexpressed in podocytes [102] (Fig. 23a). Podocytes expressing 
ACREB were preincubated with forskolin for 14 hours and treated with 200 ?M 
palmitic acid for 48 hours. Either GFP or the empty vector was used as a control. 
Apoptotic and necrotic levels were lower in ACREB expressing cells compared to 
controls. Nevertheless, ACREB could not revert the beneficial effect of forskolin, e.g 
forskolin prevented apoptosis by 30 ± 7% in empty vector-transduced podocytes and 
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by 34 ± 1% in ACREB overexpressing podocytes (Fig. 23b-d), respectively, 
indicating that the PKA-CREB is not directly involved in the beneficial effect of 
forskolin on palmitic acid-induced podocyte death. However, ACREB overexpressing 
podocytes showed increased levels of CREB, which might be explained by a 
compensatory mechanism and might be responsible for the ineffectiveness of ACREB 
in reversing the protective effect of forskolin (Fig. 23a). 
 
 
Figure 23: A dominant negative CREB does not impair the effect of forskolin on 
palmitic acid-induced cell death. a) Western blot analysis of ACREB expression in ACREB 
overexpressing and control (empty vector) podocytes. b-d) ACREB overexpression does not 
revert the effect of forskolin on palmitic acid-induced podocyte death. Bar graphs represent 
mean fold-increase ± SD of apoptotic (a), necrotic (b) and apoptotic + necrotic (c) cells. 
Vehicle (DMSO)-treatment was set to 1. 
3.3.5 Forskolin is obviously acting not directly on the intrinsic apoptotic 
pathway 
Considering the fact that 16 hours treatment with 250 ?M palmitic acid led to 
increased cytosolic cytochrome c (Fig. 5c) a potential candidate induced by CREB 
that might be involved in the protective effect of forskolin is the antiapoptotic Bcl-2 
[137]. Bcl-2 prevents mitochondrial cytochrome c release by direct interaction with 
proapoptotic Bax/Bak and by inhibition of mitochondrial membrane permeability 
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transition (MPT) [138]. To examine a possible involvement of Bcl-2 protein levels 
were analyzed after 0.5, 1, 2 and 24 hours of forskolin-treatment. Comparable to 
CREB phosphorylation Bcl-2 levels were most enhanced after 30 minutes followed 
by a gradual decrease (Fig. 22a). Surprisingly, DMSO (vehicle)-treatment was 
increasing Bcl-2 content over time (Fig. 22a). Furthermore, no significant changes in 
Bcl-2 expression levels were determined in forskolin-treated podocytes incubated 
with palmitic acid for 24 hours (data not shown). These results do not support a 
crucial role for Bcl-2 in the prevention of forskolin from palmitic acid-induced 
apoptosis and necrosis. Consistent to the Bcl-2 data, forskolin did not affect 
mitochondrial cytochrome c release in palmitic acid-treated podocytes (data not 
shown). 
3.3.6 Forskolin generally protects podocytes from ER-stress-induced apoptosis 
and necrosis 
The protective effect of forskolin and the different effect of the two cAMP analogons 
are indicating an involvment of PKA. However, data are indicating that forskolin is 
not acting via PKA-CREB and furthermore is not affecting the mitochondrial 
apoptotic pathway. Nevertheless, forskolin is reducing the induction of ER-stress, 
which has been shown to be crucially involved in mediating palmitic acid-induced 
podocyte death. In order to examine a direct effect of forskolin on attenuating the 
induction of ER-stress, it has been investigated if forskolin could prevent from 
tunicamycin- and thapsigargin-induced podocyte death. Podocytes were pretreated 
with 1 ?M forskolin for 14 hours and subsequently treated with either 1 ?M 
thapsigargin or 2 ?g/ml tunicamycin for 48 hours. Annexin V and PI staining revealed 
that forskolin moderately prevented the cytotoxic effect of both thapsigargin and 
tunicamycin (Fig. 24a, b). Forskolin suppressed apoptosis and necrosis in 
thapsigargin-treated cells by 25 ± 9% (p < 0.01) and 27 ± 7% (p < 0.01), respectively 
(Fig. 24a). The beneficial effect on tunicamycin-treatment was less pronounced: 22 ± 
9% (p < 0.05) less necrosis but not significantly less apoptosis (21 ± 17%; p = 0.1; 
Fig. 24b). 
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Figure 24: Forskolin ameliorates survival of thapsigargin- and tunicamycin-treated 
podocytes. Podocytes were pretreated with 1 ?M forskolin or DMSO for 14 hours and 
subsequently treated with 1 ?M thapsigaragin (a) or 2 ?g/ml tunicamycin (b). Vehicle 
(DMSO)-treatment was used as control. Bar graphs represent mean percentages ± SD of 
apoptotic and necrotic podocytes (n = 3; * p < 0.05, **p < 0.01). 
 
Taken together, these data indicate that forskolin protects from palmitic acid-induced 
cell death not involving an upregulation of Bcl-2 or an attenuation of cytochrome c 
release. In addition the lack of an effect of ACREB overexpression in podocytes does 
not support a causal role of CREB in podocytes treated with forskolin. Interestingly, 
forskolin is ameliorating podocyte survival when treated with two other independent 
ER-stress inducers, thapsigargin and tunicamycin, indicating a direct interference with 
the apoptotic cascades of the UPR. 
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4. DISCUSSION 
4.1 Palmitic acid induces podocytes death; involvement of ER-stress 
and CHOP 
The present study uncovered that the saturated palmitic acid induces podocyte cell 
death (Fig. 3 and Fig. 4). These findings are of clinical interest because insulin 
resistance is associated with increased plasma levels of long-chain FFAs, and DN is 
characterized by apoptosis and loss of podocytes that preceed albuminuria and renal 
dysfunction in DN, both in type I and type II diabetes [10, 11, 16, 25, 139]. 
Previous studies found that high glucose [25], TGF-ß [36, 140], the RAAS system 
[32, 141], and AGEs [28, 29] can also induce apoptosis of podocytes. 
The identification of palmitic acid as another proapoptotic factor for podocytes may 
be of clinical relevance in the setting of type II diabetes because FFAs are elevated in 
patients with obesity and insulin resistance even before hyperglycemia arises [142]. 
FFAs can also be elevated in type I diabetic subjects [143]. Moreover, similar to DN, 
obesity-related glomerulonephropathy is characterized by a decreased density of 
podocytes [144], raising the intriguing possibility that FFA-induced podocyte 
apoptosis may also contribute to the development and progression of obesity-related 
glomerular disease. 
The detection of palmitic acid-induced ER-stress in podocytes is in line with similar 
findings in other cell types [52, 54, 56, 61, 62]. In pancreatic ß cells, overexpression 
of the ER chaperone BiP can partially prevent palmitic acid-induced apoptosis [55], 
implying that the upregulation of BiP (Fig. 6a) is part of an adaptive podocyte-
protective mechanism. In contrast, the strong upregulation of CHOP (Fig. 6b, c) 
makes CHOP a good candidate as mediator of palmitic acid-induced podocyte 
apoptosis because CHOP is critically involved in ER-stress induced apoptosis [98, 
145]. Consistent with the strong induction of CHOP we also observed palmitic acid-
induced XBP-1 splicing (Fig. 6d), which is directly involved in transcriptional 
regulation of CHOP [112]. 
In further experiments we could definitely establish a causative role for CHOP in 
palmitic acid-induced podocyte apoptosis, as gene-silencing of CHOP protects 
podocytes from palmitic acid-induced death (Fig. 7d-f and Fig. 8b-d). This outcome is 
consistent with the known role of CHOP in ER-stress induced apoptosis [98, 145]. 
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Importantly, ER-stress has been implicated in podocyte apoptosis caused by AGEs 
[29] or excessive protein loading [146], but a causative role of CHOP under these 
conditions remains to be established. 
We also tested the chemical chaperones 4-PBA and TUDCA. TUDCA did not show a 
protective effect on palmitic acid-induced cell death (Fig. 9), whereas 4-PBA was 
even deleterious (data not shown). Interestingly, these results are in line with 
observations in pancreatic ß cells [93]. It might be explained by the fact that palmitic 
acid overload is shifting the ER fatty acid composition and is directly disrupting ER 
integrity and structure [87]. Moreover, in pancreatic ß cells it has been shown that 
palmitic acid is not leading to increased mis- or unfolded proteins in the ER but rather 
to impaired ER-to-Golgi protein trafficking, which may trigger ER-stress [119]. 
The notion that CHOP plays a pathogenic role in experimental DN is supported by the 
observation that CHOP is upregulated in two rodent models of DN [121, 122], and 
CHOP-deficient mice are protected from DN as well as age-related albuminuria [122]. 
However, in patients with DN, although we found an upregulation of BiP by 
quantitative RT-PCR analysis in microdissected glomeruli (Fig. 11) as previously 
reported in the tubulointerstitial compartment [147], CHOP mRNA expression was 
unchanged in the tubulointerstitial compartment [147] and down regulated in 
glomeruli (Fig. 11). Clearly, future studies will be required to address potential 
differences between our in vitro data and results in murine models with that of human 
DN to determine the precise role of CHOP in patients with DN. 
An interesting additional finding was the observation that proapoptotic stimuli such as 
high glucose and TGF-ß did not lead to an induction of CHOP in podocytes (Fig. 6d), 
suggesting that ER-stress is not involved in apoptosis caused by high glucose and 
TGF-ß. However, high glucose was able to amplify the induction of BiP and CHOP 
by palmitic acid (Fig. 6d), and high glucose enhances apoptosis mediated by palmitic 
acid in podocytes (Kapil Kampe, unpublished data) similarly as in pancreatic ß cells 
[53].  
4.2 Palmitoleic and oleic acid attenuate palmitic acid-induced ER-
stress and prevent palmitic acid-induced podocyte death  
Palmitoleic and oleic acid could prevent palmitic acid-induced podocyte apoptosis 
and necrosis (Fig. 10). The antagonistic effects of palmitic acid and the 
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monounsaturated palmitoleic and oleic acid on cell death in podocytes (Fig. 10) are 
analogous to data from other cell types [52, 53, 62, 92]. Consistent with the outcome 
that CHOP is an important player in mediating palmitic acid-induced apoptosis the 
addition of MUFAs also prevented from the induction of CHOP (Fig. 10). In addition, 
palmitoleic and oleic acid increased protein levels of the chaperone BiP (Fig. 10), 
which is known to prevent palmitic acid-induced apoptosis [55], thus BiP production 
might partially explain the protective effects of MUFAs. 
4.3 Stearoyl-CoA desaturases protect from palmitic acid-induced 
cell death 
Consistent with the protective effects of MUFAs on palmitic acid-induced cell death 
induction of cell autonomous fatty acid desaturases ameliorates survival of palmitic 
acid-treated podocytes. First, we could demonstrate that TO901317 (TO), an LXR 
agonist [129] that is leading to increased levels of desaturases, partially prevents 
palmitic acid-induced cell death (Fig. 12b), which is in line with results from other 
cell types [89, 148]. TO is strongly inducing SCD-1 and SCD-2 in podocytes (Fig. 
13c), whereas the effect of TO on SCD-3 and SCD-4 was not significant (Fig. 13c). 
Gene-silencing (Fig. 15) and overexpression (Fig. 16) experiments indicate that the 
protective effect of TO can be largely attributed to the induction of SCD-1 and SCD-
2. Moreover, SCD-1 and SCD-2 are able to compensate for each other as only 
combined silencing of both isoforms can revert the beneficial effect of TO on palmitic 
acid-induced podocyte apoptosis (Fig. 14 and Fig. 15). 
An interesting finding was that SCD-2 is apparently predominant in cultured 
podocytes (Fig. 13b), which differs from whole kidney expression where SCD-1 is 
the commonest isoform (Fig. 13a) as previously reported [126]. 
Although the mechanisms of how MUFAs are protecting from SFA-induced 
lipotoxicity are not completely understood, data are indicating that increased fatty 
acid storage as TGs and fatty acid oxidation may help cells to reduce biological active 
SFAs and to avoid the formation of cytotoxic metabolites such as DAGs and 
ceramides [50]. Using palmitic acid tracing experiments we observed that TO 
increases the ratio of [
3
H]-palmitic acid-containing TGs to DAGs (Fig. 17a). The 
effect was even more pronounced in podocytes coincubated with oleic acid (Fig. 17b). 
Whereas the effect of TO is mainly due to an increase in TGs, oleic acid decreased 
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[
3
H]-palmitic acid recovered in the DAG fraction and increased [
3
H]-palmitic acid in 
the TG fraction (Fig. 17c, d). Previously, increased TG synthesis has been associated 
with a reduction in intracellular levels of DAGs and ceramides and it has been 
suggested that this is preventing from their harmful actions [65, 149]. In this study we 
did not measure [
3
H]-palmitic acid integrated into ceramides as fumonisin B1, a 
ceramide synthetase inhibitor, showed no protection from palmitic acid-induced 
lipotoxicity in podocytes (data not shown). As TO-treatment has no significant effect 
on palmitic acid-derived FFA incorporated into DAGs, the beneficial action on 
palmitic acid-induced podocyte death cannot be explained by this mechanism (Fig. 
17c). However, there is data indicating that DAG-mediated lipotoxicity might be 
depending on the saturation of fatty acids incorporated in DAGs [150], and we 
speculate that TO might have increased palmitic acid-derived MUFAs incorporated in 
DAGs. In addition, the increased amount of [
3
H]-palmitic acid recovered in TGs after 
treatment with TO is likely protective as palmitic acid is stored away in a “safe lipid 
pool” [50]. 
Even though a shift to increased TG synthesis and lipid storage may help the cells to 
cope with lipotoxicity, the role of SCDs and increased TG content is rather debated. 
SCD-1 deficiency in mice is attenuating high fat diet-induced obesity and insulin 
resistance [151] but is as well promoting inflammation and atherosclerosis [152]. 
Importantly, the favorable effect of SCD-1 deficiency is mainly associated with 
altered skin lipid composition leading to decreased skin insulation and a resulting 
substantial increase in energy expenditure, which may mainly explain the decreased 
insulin resistance in this genetic model [153]. 
The role of ectopic TG storage in non-adipose tissue is controversial. Insulin resistant 
obese rodents [154, 155] show increased intramuscular TG content and synthesis rates 
whereas in humans the so-called ‘athletes paradox’ indicates that ectopic fat 
accumulation is not per se negative as endurance trained people have higher insulin-
sensitivity but as well increased intramuscular TG stores [156, 157]. Furthermore 
transgenic mice overexpressing the TG-synthesizing enzyme DAG acyltransferase 1 
(DGAT1) in the heart show increased TG content associated with improved heart 
function [158]. 
In addition, we evaluated the effect of TO and oleic acid on oxidation of palmitic acid 
using [
3
H]-palmitic acid. Whereas oleic acid induces ß-oxidation no increase results 
from the treatment with TO (Fig. 18). These differences in the synthesis of TGs and 
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the upregulation of ß-oxidation may explain the more potent effect of oleic acid in 
protecting podocytes from palmitic acid-induced death. In summary, the in vitro 
observations of this study indicate that induction of desaturases might prevent 
podocyte apoptosis and thus glomerular podocyte loss and attenuate the pathogenesis 
of DN. However, further studies are necessary to delineate the exact role of 
desaturases in the development and pathogenesis of DN. 
The importance of fatty acid oxidation in ameliorating the detrimental effect of 
palmitic acid is supported by additional experiments using Aicar, an AMP-activated 
protein kinase (AMPK) agonist, to increase fatty acid oxidation and etomoxir, an 
inhibitor of the carnitine palmitoyl transferase 1 (CPT1), which is the rate-limiting 
enzyme in ß-oxidation. Stimulation of fatty acid oxidation by Aicar is protective, 
whereas inhibition of fatty acid oxidation is detrimental for palmitic acid-incuded 
podocyte damage (Kapil Kampe, unpublished data). 
Importantly, the potentially critical contribution of reduced ß-oxidation in the 
pathogenesis of DN is strongly supported by a recent large-scale genome wide 
association study in patients with type II diabetes and DN [159]. This study found a 
polymorphism in a noncoding region of acetyl-CoA carboxylase ß (ACCß) with a 
strong association with proteinuria. ACC? activity inhibits fatty acid oxidation and 
the DN-risk single nucleotide polymorphism (SNP) of ACC? results in a higher 
ACC? expression [159] indicating that impaired fatty metabolism in addition to 
elevated free fatty acid levels may be critical in the pathogenesis of DN. The original 
finding of this association in Japanese patients has been confirmed in independent 
cohorts including a large cohort from China [160]. 
4.4 The protective effect of increased cAMP levels on palmitic acid-
induced podocyte death 
The present study uncovered that the adenylate cyclase agonist forskolin is 
ameliorating survival of palmitic acid-treated podocytes (Fig. 19a and Fig. 20a). 
Similarly, the constitutively active cAMP analogon Br-cAMP is protective (Fig. 20a), 
which suggests that increased cAMP levels are responsible for the favorable effect of 
forskolin. In pancreatic ß cells the protective effect of forskolin on palmitic acid-
induced lipotoxicity has been attributed to increased expression levels of the ER 
chaperone BiP [131]. Contrariwise, forskolin reduces the induction of BiP in 
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podocytes exposed to palmitic acid (Fig. 19b) and the favorable effect of forskolin 
cannot be explained by a protective upregulation of BiP. However, forskolin 
prevented upregulation of the proapoptotic transcription factor CHOP (Fig. 19b), 
which certainly contributes to its protective effect although further studies need to be 
done to elucidate the underlying mechanisms.  
Experiments using 8-CPT-2Me-cAMP, a cAMP analogon favoring Epac [134], are 
indicating that the beneficial effect of forskolin and cAMP is mainly resulting from 
PKA signaling (Fig. 20b), though we can not completely exclude that the less 
protective effect compared to 8-Br-cAMP (Fig. 20b) results from unspecific lack of 
equipotency. The PKA inhibitor H89 is reversing the protective effect of forskolin to 
some extent (Fig. 21). However, as H89 is itself aggravating palmitic acid-induced 
podocyte death, an essential involvment of PKA in the protective effect of forskolin 
needs confirmation, though the deleterious effect of H89 indicates a prosurvival 
action of PKA. 
Looking downstream of PKA, forskolin leads to phosphorylation of the transcription 
factor CREB and induction of its downstream target Bcl-2 (Fig. 22a) [136, 161]. 
However, the protective effect of forskolin seems not to involve this pathway as 
forskolin does not prevent cytochrome c release into the cytoplasm (data not shown), 
and genetic overexpression of a dominant negative form of CREB, ACREB [102] is 
not affecting the effect of forskolin on palmitic acid-induced podocyte apoptosis and 
necrosis (Fig. 23).  
An interesting finding is the fact that forskolin is protecting from the distinct and 
independent ER-stressors tunicamycin and thapsigargin (Fig. 24). This observation is 
indicating that forskolin and elevated levels of cAMP have a more general effect on 
the induction of ER-stress and the UPR in podocytes. 
Increased cAMP levels have also been attributed to glomeruloprotective effects in 
vivo. Rolipram, an inhibitor of the type IV phosphodiesterase, the major cAMP 
metabolizing enzyme in podocytes, has been effective in the prevention and treatment 
of experimental crescentic glomerulonephritis, a proteinuric kidney disease, which 
often progresses rapidly to ESRD [162]. In addition, inactivation of AC1 is resulting 
in increased susceptibility to experimental proteinuria induced by intraperitoneal 
injections of BSA, which is associated with increased local foot process effacement 
[163]. Forskolin has been shown to rearrange the actin cytoskeleton and reinforce the 
integrity of cell-cell contacts in podocytes [164], and PKA inhibition has been shown 
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to prevent actin cytoskeleton formation [165]. In addition, it has been observed that 
synaptopodin, an actin-associated protein [166], is phosphorylated directly by PKA 
and thus prevented from degradation [167]. As a consequence it would be reasonable 
to test the effect of forskolin and increased cAMP levels on synaptopodin stability and 
its subsequent influence on the actin cytoskeleton in palmitic acid-treated podocytes, 
which might be a link to the favorable effect of forskolin on palmitic acid-induced 
podocyte death. Moreover, it would be of interest to investigate the effect of forskolin 
and increased cAMP levels on the pathogenesis DN. 
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5. CONCLUSION 
The uncovering of the saturated palmitic acid as another proapoptotic factor of the 
diabetic milieu, which is causally linked to ER-stress induction, might be of clinical 
relevance as podocyte apoptosis is an early event in the development and 
pathogenesis of DN and as plasma FFA levels are elevated in obese and insulin 
resistant patients before the onset of hyperglycemia [10, 11, 16, 25, 36, 142]. 
However, the fact that MUFAs prevented SFA-mediated podocyte death and that in 
vivo FFAs consist of both, SFAs and MUFAs, makes it difficult to evaluate the 
contribution of elevated FFAs in the pathogenesis of DN. Nevertheless, increased 
SFA intake may lead in the longterm to increased podocyte apoptosis and thus 
contribute to the development and pathogenesis of DN. 
Examining mechanisms to rescue podocytes from palmitic acid-induced death in vitro 
revealed two promising strategies. First, induction of cellular autonomous desaturases, 
converting SFAs into MUFAs and subsequently leading to increased TG levels, 
protected podocytes from palmitic acid-induced apoptosis. Second, raising 
intracellular cAMP levels ameliorated survival of podocytes treated with palmitic 
acid. So far, the beneficial effect could be linked to a general reduction of ER-stress 
initiation. 
Together, further studies are necessary to unravel the mechanisms how palmitic acid 
is inducing ER-stress and apoptosis in podocytes and to delineate the role of 
desaturases and cAMP levels in preventing this process. Moreover, it would be of 
interest to interfere with these pathways in mice, in particular podocyte-specifically, 
to learn more about its relevance in vivo. 
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Sieber J, Lindenmeyer MT, Kampe K, Campbell KN, Cohen
CD, Hopfer H, Mundel P, Jehle AW. Regulation of podocyte
survival and endoplasmic reticulum stress by fatty acids. Am J
Physiol Renal Physiol 299: F821–F829, 2010. First published July
28, 2010; doi:10.1152/ajprenal.00196.2010.—Apoptosis of podo-
cytes is considered critical in the pathogenesis of diabetic nephropathy
(DN). Free fatty acids (FFAs) are critically involved in the pathogen-
esis of diabetes mellitus type 2, in particular the regulation of
pancreatic  cell survival. The objectives of this study were to
elucidate the role of palmitic acid, palmitoleic, and oleic acid in the
regulation of podocyte cell death and endoplasmic reticulum (ER)
stress. We show that palmitic acid increases podocyte cell death, both
apoptosis and necrosis of podocytes, in a dose and time-dependent
fashion. Palmitic acid induces podocyte ER stress, leading to an
unfolded protein response as reflected by the induction of the ER
chaperone immunoglobulin heavy chain binding protein (BiP) and
proapoptotic C/EBP homologous protein (CHOP) transcription factor.
Of note, the monounsaturated palmitoleic and oleic acid can attenuate
the palmitic acid-induced upregulation of CHOP, thereby preventing
cell death. Similarly, gene silencing of CHOP protects against
palmitic acid-induced podocyte apoptosis. Our results offer a rationale
for interventional studies aimed at testing whether dietary shifting of
the FFA balance toward unsaturated FFAs can delay the progression
of DN.
diabetic nephropathy; apoptosis; endoplasmic reticulum; stress;
palmitic acid
DIABETIC NEPHROPATHY (DN) is the major cause of end-stage
renal disease (ESRD) in many industrialized countries, and as
the prevalence of type 2 diabetes is much greater, most diabetic
patients starting renal replacement therapy today have type 2
diabetes (1, 25). Podocyte injury and loss are critical events in
the course of DN (58) and precede albuminuria and renal
dysfunction (9, 35, 42, 50, 53). Type 2 diabetes mellitus is
characterized by hyperglycemia and dyslipidemia with in-
creased plasma levels of long-chain free fatty acids (FFAs) (43,
55). Saturated FFAs such as palmitic acid are proapoptotic
factors in other cell types, including pancreatic -cells (28, 33,
48) and hepatocytes (29, 57). Monounsaturated FFAs such as
palmitoleic or oleic acid are able to prevent/attenuate palmitic
acid-induced impaired insulin secretion and increased apopto-
sis of pancreatic -cells (27), and diets rich in unsaturated
FFAs were shown to lower glucose levels in type 2 diabetic
mice (54). It is now widely accepted that a disbalance between
saturated and unsaturated FFAs critically contributes to the
pathogenesis of type 2 diabetes (37).
Previous studies with cultured human mesangial cells dem-
onstrated that palmitic acid stimulates apoptosis that can be
prevented by unsaturated FFAs (36). However, as it stands, the
role of FFAs in the pathogenesis of DN and their role in
podocyte viability are largely unknown. In cultured podocytes,
palmitic acid leads to insulin resistance and blockade of insu-
lin-dependent glucose uptake (21), reflecting profound alter-
ations in podocyte function. In proteinuric kidney disease,
FFAs bound to albumin are filtered and reabsorbed by the
proximal tubule, which may contribute to tubulointerstitial
inflammation and fibrosis (51, 52).
The endoplasmic reticulum (ER) is the organelle where
secretory and membrane proteins are folded. Correctly folded
proteins exit the ER and are transported to the Golgi and other
destinations within the cell, but mis- or unfolded proteins are
retained in the ER (44). The accumulation of unfolded proteins
constitutes a form of cellular stress that has been termed ER
stress. Importantly, the aforementioned toxicity of palmitic
acid involves ER stress (15, 18, 33, 56, 57). As a result of ER
stress, several signaling pathways, collectively known as the
unfolded protein response (UPR), are being activated, thereby
maintaining proper ER function. This involves attenuation of
translation and transcriptional induction of ER chaperones,
whose functions are to increase the folding capacity of the ER
and to prevent protein aggregation (17, 26). Under conditions
with severe ER stress, however, the protective mechanisms
activated by the UPR are not sufficient and a particular branch
of the UPR evolves leading to induction of the proapoptotic
transcription factor C/EBP homologous protein (CHOP; also
known as DDIT3), which can trigger apoptosis (61). The
expression of CHOP is mainly regulated at the transcriptional
level by several transcription factors, including X-box binding
protein-1 (XBP-1) (41). Of note, only the spliced form of
XBP-1 has transcriptional activity (60).
The induction of ER stress markers has been described in
human kidney biopsies of different glomerulopathies, includ-
ing membranous nephropathy, focal segmental glomeruloscle-
rosis, and minimal change disease (3, 32). Gene expression
analysis of the tubulointerstitial compartment of renal biopsies
obtained from patients with DN found a significant upregula-
tion of major genes involved in the UPR, including the ER
chaperones BiP (also known as HSPA5 or GRP78) and hyp-
Address for reprint requests and other correspondence: A. W. Jehle, Dept. of
Biomedicine, Molecular Nephrology, Rm 303, Univ. Hospital Basel, Hebel-
strasse 20, 4031 Basel, Switzerland (e-mail: andreas.jehle@unibas.ch).
Am J Physiol Renal Physiol 299: F821–F829, 2010.
First published July 28, 2010; doi:10.1152/ajprenal.00196.2010.
0363-6127/10 Copyright © 2010 the American Physiological Societyhttp://www.ajprenal.org F821
?????
?????????????
???????????????????????
?
??
????????????
?
  A-III 
 
oxia-upregulated 1, but no changes in the expression of pro-
apoptotic CHOP (22).
The objectives of the present study were to investigate the
effects of palmitic acid, a saturated FFA, and monounsaturated
FFAs such as palmitoleic or oleic acid on podocyte cell death
and the involvement of ER stress in this process. In addition,
we explored the mechanistic role of the proapoptotic transcrip-
tion factor CHOP in palmitic acid-induced podocyte cell death
by gene silencing of CHOP using a specific short-hairpin (sh)
RNA.
MATERIALS AND METHODS
Materials. Palmitic acid, palmitoleic acid, oleic acid, and essential
fatty acid-free BSA were purchased from Sigma, anti-BiP and anti-
activated caspase 3 antibodies from Cell Signaling, anti-CHOP from
Santa-Cruz Biotechnology, and anti--actin from Sigma. The horse-
radish peroxidase-conjugated secondary antibodies were obtained
from Dako and Jackson. The primary antibodies were applied at
dilutions of 1:1,000 in blocking solution (5% milk in TBS-Tween)
except anti-CHOP (1:200) and anti- -actin (1:100,000). Alexa 647
annexin V and propidium iodide (PI) were purchased from Invitrogen.
Cell culture. Podocytes were cultured as described before (39).
Briefly, conditionally immortalized mouse podocytes were cultured un-
der permissive conditions (33°C) in RPMI-1640 supplemented with 10%
FBS, penicillin/streptomycin (all from Invitrogen), and interferon- (Cell
Sciences) on type I collagen (BD Biosciences). Differentiation was
induced by thermoshift to 37°C without interferon- in six-well plates
(apoptosis assays) and 10-cm dishes (protein isolation). All experiments
were performed with cells that had been allowed to differentiate for at
least 11 days.
Fatty acid preparation. Fatty acids were prepared as described
previously (23). In brief, 20 mM solutions of palmitic, palmitoleic, or
oleic acids in 0.01 M NaOH (vehicle) were incubated at 70°C for 30
min and complexed to 10% BSA in a molar ratio of 6.6:1, shaken
overnight at 37°C under N2-atmosphere, sonicated for 10 min, sterile
filtrated, and stored at 20°C. Before use, the complexes were heated
at 60°C for 15 min followed by dilution in medium. The fatty acid
concentrations were determined with a commercial kit according to
the manufacturer’s instructions (Wako). The endotoxin concentration
was measured using a commercial kit (GenScript), and the final
concentration in all experiments was equal or below 0.5 ng/ml. BSA
used for control experiments was prepared and handled exactly the
same as BSA complexed to FFAs.
Apoptosis assay. Podocyte apoptosis and necrosis were determined
by flow cytometry exactly as recently reported (2). Briefly, podocytes
were trypsinized and resuspended in annexin V binding buffer (10
mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). Annexin V
staining was applied for 15 min at room temperature (see producer
protocol) and before analysis 0.5 g PI was added. For the assay,
20,000–25,000 cells were analyzed by flow cytometry (Dako).
RT-PCR analysis of XBP-1 mRNA splicing. Total RNA was ex-
tracted with a Nucleospin kit (Macherey-Nagel), and first-strand
cDNA was synthesized using oligo(dT) primers (Fermentas). Ampli-
fication (initial denaturation at 94°C for 1 min, 30 cycles of PCR at
94°C for 30 s, 58°C for 30 s, and 72°C for 1 min, and a final extension
at 72°C for 10 min) was performed with a pair of primers correspond-
ing to nucleotides 392–415 (TGAGAACCAGGAGTTAAGAA-
CACGC) and 720–696 (TTCTGGGTAGACCTCTGGGAGTTCC)
of mouse XBP-1 cDNA (AF027963) (40). PCR products were sepa-
rated by electrophoresis on 2.5% agarose gels and visualized by
ethidium bromide staining.
Western blotting. Podocytes were washed with ice-cold PBS and
scraped into 200 l RIPA lysis buffer (50 mM Tris·HCl, pH 7.5, 200
mM NaCl, 1% Triton, 0.25% deoxycholic acid, 1 mM EDTA, 1 mM
EGTA) containing EDTA-free protease inhibitors (Roche) and phos-
phatase inhibitors (Pierce). To include the floating and detached cells,
the culture medium and PBS (the cells were washed with) were
collected, centrifuged (530 g), and resuspended in 20 l lysis buffer.
The pooled cells were lysed mechanically and rotated for 1 h at 4°C.
To remove nuclei, the samples were spun down (10,000 rpm, 10 min)
and the protein concentration of the supernatant was determined by
DC protein assay (Bio-Rad). Then, 30–80 g of protein/well were
loaded on 12 or 15% gels and separated by SDS-PAGE. Transfer to
nitrocellulose membranes was applied at 100 V in the cold room for
1 h, and the blots were blocked for 2 h with 5% milk powder in
TBS-Tween. Primary antibodies were applied overnight, secondary
antibodies for 1 h. The immunoblots were detected by enhanced
chemiluminescence (Pierce) on Kodak BioMax light films (Sigma).
Lentivirus production and CHOP knockdown. A CHOP-specific
oligonucleotide (GGAAACGAAGAGGAAGAATCA) (11) was cloned
into a FUGW vector coexpressing green fluorescent protein under a
ubiquitin promotor. A 21-nt scrambled sequence (GACCGCGACTCGC-
CGTCTGCG) with no murine homology served as a nonsilencing control
(2). Lentivirus production was performed as previously reported (13). In
brief, HEK293 cells were transfected using Fugene (Roche) with the
FUGW vector and two helper plasmids, vesicular stomatitis virus (VSV)
G protein and 8.9. After 72 h, the supernatant was spun down at 780 g
and filtered using a filter with 0.45-m pore size. Podocytes were
transduced by adding virus-containing medium after 5-min pretreatment
with 10 g/ml polybrene (Sigma). All experiments were performed 4
days after viral transduction (2).
Statistical analysis. Data are expressed as means  SD unless
otherwise indicated. The significance of differences was calculated
with a two-sided, unpaired t-test unless otherwise indicated.
RESULTS
Palmitic acid induces podocyte cell death. First, we inves-
tigated whether palmitic acid may also induce podocyte cell
death as reported for other cell types, e.g., pancreatic -cells
(28, 33, 48). Palmitic acid complexed to BSA in concentrations
from 125 to 500 M enhanced cell death of podocytes in a
concentration-dependent manner (Fig. 1). Figure 1A shows
representative flow cytometry data with the abscissa and ordi-
nate representing the fluorescence intensity of annexin V and
PI, respectively. In BSA not complexed to palmitic acid (BSA
containing control medium), 5.2  0.1% of podocytes were
annexin V-positive/PI-negative cells, representing early apop-
totic podocytes, and 5.9  0.9% were annexin V positive/PI
positive, representing late apoptotic/necrotic cells (Fig. 1B).
Palmitic acid increased apoptosis significantly at 250 (9.1 
0.9%, P  0.01; Fig. 1B) and at 500 M (14.0  0.2%, P 
0.01; Fig. 1B). We also found a dose-dependent increase in
necrotic cells (at 500 M, 17.3 1.2%, P 0.01; Fig. 1B). To
be able to detect an effect of low palmitic acid concentrations
(125 and 250 M), a relatively long incubation time (38 h) was
chosen for the experiments displayed in Fig. 1. Next, we tested
the time dependency of palmitic acid-induced podocyte apop-
tosis by analyzing cell death over time after exposure to 500
M palmitic acid (Fig. 2A). Palmitic acid induced cell death,
both apoptosis and necrosis, in a time-dependent manner, and sig-
nificant differences became apparent at 24 h (Fig. 2, B and C).
After 48 h, a 2.5- to 3-fold increase in apoptotic and necrotic
podocytes was observed (P  0.01; Fig. 2, B and C). Of note,
the increase in annexin V/PI double-positive late apoptotic/
necrotic cells was underestimated by flow cytometry, as more
floating cellular debris were formed in the supernatants of cell
pellets used for flow experiments over time. This was reflected
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in a decreased total number of cells recovered in cell pellets
after 34 and 48 h (P  0.05; Fig. 2D).
Palmitic acid activates effector caspase 3. To confirm the
effect of palmitic acid on podocyte apoptosis with a second,
independent approach, we examined the activation of effector
caspase 3 by Western immunoblotting using an antibody spe-
cific for cleaved and therefore activated caspase 3 (49) (Fig. 3).
As activation of caspase 3 typically occurs before externaliza-
tion of phosphatidylserine (30) as assessed by annexin V
staining in the flow cytometry assay, we incubated podocytes
with 500 M palmitic acid for 1 or 16 h (Fig. 3A). For
staurosporine (positive control), a faint band for cleaved
caspase 3 was seen as early as after 1 h, whereas for palmitic
acid a band for cleaved caspase 3 was seen after 16 h (Fig. 3A).
Consistent with the flow cytometry data (Fig. 1), cleaved
caspase 3 could be observed at lower concentrations of
palmitic acid with a faint band at a concentration of 125 M
and a strong band at 250 and 500 M (Fig. 3B).
Palmitic acid induces ER stress in podocytes. The toxicity of
palmitic acid has been attributed to the induction of ER stress
(15, 18, 33, 56, 57). Therefore, we studied the effect of palmitic
acid on protein levels of BiP, an ER chaperone that is upregu-
lated during ER stress (19). We observed a strong upregulation
of BiP protein expression after incubation with 500 M
palmitic acid for 16 and 24 h (P  0.01, Fig. 4A, and
Supplemental Fig. S1A; supplemental material for this article
is available online at the Journal website). In addition, the
proapoptotic transcription factor CHOP, which is typically
upregulated during severe ER stress (61), was increased nine-
fold after 24 h (P  0.01, Fig. 4B).
As the effect of palmitic acid on podocyte cell death started
to become visible at a concentration of 125 M and even more
at 250 M (Fig. 1), we tested whether palmitic acid at 125 and
250 M could also upregulate BiP and CHOP expression.
Indeed, already lower concentrations of palmitic acid upregu-
lated CHOP (Fig. 4C) and BiP expression (Supplemental Fig.
S1B). Moreover, as the induction of CHOP expression should
precede palmitic acid-induced cell death, we explored changes
in CHOP expression at an earlier time point (6 h). Taken
together, we found a dose- and time-dependent increase in
CHOP protein levels as early as after 6 h (Fig. 4C).
XBP-1 is involved in the transcriptional activation of CHOP
in ER stress, but only the spliced form of XBP-1 (sXBP-1) has
transcriptional activity (60). Therefore, we used RT-PCR to
amplify fragments of XBP-1 representing both the unspliced
(uXBP-1) and the spliced (sXBP-1) forms of XBP-1 mRNA.
Palmitic acid and tunicamycin (Tn), an established inducer of
ER stress, strongly induced sXBP-1 and an additional slowly
migrating band (Fig. 4D). The slowly migrating band repre-
sents a hybrid form of uXBP-1 and sXBP-1 (hXBP-1), which
can form during annealing in the last PCR step (47). XBP-1
splicing was increased as early as after 4 h after exposure to
palmitic acid (data not shown), implying a potential role for
XBP-1 splicing in transcriptional activation of CHOP.
High glucose concentrations (50) and TGF- at a concen-
tration of 5 ng/ml (62) can also induce podocyte injury and
death. Therefore, we tested whether high glucose or TGF- can
induce BiP or CHOP expression. Neither high glucose (22
mM) nor TGF- induced CHOP (Fig. 4E), but TGF- (5
Fig. 1. Palmitic acid induces apoptosis and necrosis of podocytes in a dose-dependent manner. A: representative flow cytometry results for podocytes exposed
to increasing concentrations of palmitic acid (125–500 M) or BSA (at a concentration equivalent to cells treated with 500 M palmitic acid complexed to BSA)
for 38 h. The abscissa and ordinate represent the fluorescence intensity of annexin V Alexa 647 and propidium iodide (PI), respectively. B: quantitative analysis
of palmitic acid-induced podocyte cell death. Bar graph represents the mean percentages  SD of annexin V-positive/PI-negative (early apoptotic) and annexin
V-positive/PI-positive (late apoptotic/necrotic) podocytes (n 	 3). *P  0.05, **P  0.01.
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ng/ml) alone or in combination with high glucose induced BiP
(Fig. 4E). The weak effect of high glucose on BiP expression
was similar to the effect of mannitol, which was used to adjust
osmolality to the high-glucose condition, and therefore, the
difference in osmolality rather than a high glucose concentra-
tion may account for this observation. Staurosporine, a strong
inducer of podocyte apoptosis (2), did not increase BiP or
CHOP expression (Fig. 4E).
Fig. 2. Palmitic acid induces time-dependent podocyte apoptosis. A: palmitic acid-induced podocyte cell death was determined by annexin V/PI staining followed by flow
cytometry. B: quantitative analysis. Bar graph represents the mean fold-increase SD in annexin V-positive/PI-negative (apoptotic) cells incubated with palmitic acid or BSA
for indicated time points (n	 3). *P	 0.05, **P 0.05, ***P 0.01. C: bar graph representing the mean fold-increase SD in annexin V-positive/PI-positive (necrotic)
cells incubated with palmitic acid or BSA for indicated time points (n	 3). **P 0.05, ***P 0.01. D: bar graphs representing intact cells recovered in cell pellets (	 total
cells in culture dishes minus floating cellular debris in supernatant after centrifugation at 550g), which were used for flow experiments shown inA–C. Palmitic acid significantly
decreased the number of recovered cells after 34 and 48 h (**P  0.05), reflecting the increase in necrotic cellular debris that could not be recovered in cell pellets.
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Palmitoleic or oleic acid attenuates palmitic acid-induced
UPR and prevents podocyte cell death. In  cells of the
pancreas, certain monounsaturated FFAs can activate antiapop-
totic mechanisms (38) and suppress CHOP expression (10),
and diets rich in unsaturated FFAs can lower glucose levels in
type 2 diabetic mice (54). Therefore, we explored the effect of
500 M palmitoleic acid (C16:1) or oleic acid (C18:1) on
palmitic acid-induced podocyte cell death and CHOP induc-
tion. Palmitoleic acid and oleic acid could prevent podocyte
apoptosis and necrosis (Fig. 5, A and C). Palmitoleic acid alone
or in combination with palmitic acid also induced BiP but
strongly attenuated the induction of CHOP (Fig. 5B). Similar
results were observed when oleic acid was used instead of
palmitoleic acid (Fig. 5D).
Gene silencing of CHOP attenuates palmitic acid-induced
cell death in podocytes. CHOP is a proapoptotic transcription
factor, and CHOP deletion can protect from ER-stressed in-
duced apoptosis (61). To test whether the marked upregulation
of CHOP (Fig. 4, B and C) is mechanistically involved in
palmitic acid-induced podocyte cell death, we generated
CHOP knockdown podocytes by lentiviral infection using a
CHOP-specific shRNA (11). By immunoblotting, we observed
a marked suppression of CHOP (Fig. 6B, P  0.01) and BiP
(Fig. 6B, P 0.05) protein expression in podocytes transduced
Fig. 3. Palmitic acid activates caspase 3 in podocytes. Western blot analysis of active, cleaved caspase 3 protein steady-state levels in podocytes exposed to
staurosporine (stauro), fatty acid-free BSA (BSA), or palmitic acid (palm) is shown. A: 0.25 M staurosporine (serving as a positive control) and palmitic acid
caused a strong activation of caspase 3 after 16 h. No signal was seen after 1-h exposure to palmitic acid or after treatment with BSA (negative control). -Actin
served as a loading control. Representative results of 3 independent experiments are shown. B: dose-dependent activation of caspase 3 by palmitic acid. For
control condition (BSA), the BSA concentration equivalent to cells exposed to 500 M palmitic acid complexed to BSA was used. -Actin served as a loading
control. Representative results of 2 independent experiments are shown.
Fig. 4. Palmitic acid induced the endoplasmic reticulum (ER) chaperone immunoglobulin heavy chain binding protein (BiP) and C/EBP homologous protein
(CHOP) in podocytes. A: palmitic acid-induced upregulation of BiP (top) and quantitative analysis of BiP levels normalized to -actin (bottom). The expression
level of the control condition (BSA) was set to 100%; n	 4. *P 0.01. B: palmitic acid induced upregulation of CHOP (top) and quantitative analysis of CHOP
levels normalized to -actin (bottom). The expression level of the control condition (BSA) was set to 100%; n 	 4. *P  0.01. C: time- and dose-dependent
upregulation of CHOP protein levels by palmitic acid. For the control condition (BSA), the BSA concentration was equivalent to cells exposed to 500 M
palmitic acid complexed to BSA. -Actin served as a loading control. Representative results of 3 independent experiments are shown. D: RT-PCR of X-box
binding protein-1 (XBP-1) mRNA in podocytes treated with 500 M palmitic acid for 12 h. Tunicamycin (Tn; 5 ng/ml) was used as a positive control. In the
control condition (BSA), a strong band for unspliced (u) XBP-1 is visible, whereas sXBP-1 and hXBP-1 are strongly increased after treatment with palmitic acid
or tunicamycin. Representative results of 3 independent experiments. E. BiP and CHOP expression after exposure for 24 h as follows. Lane 1, control medium
containing 5 mM glucose and fatty acid free BSA (BSA); lane 2, control medium (BSA) supplemented with additional 17 mM mannitol (M); lane 3, control
medium (BSA) supplemented with additional 17 mM glucose [high glucose (HG)]; lane 4, BSA complexed with 500 M palmitic acid (palm); lane 5, palmitic
acid (palm) and HG; lane 6, 5 ng/ml TGF- with HG; lane 7, 5 ng/ml TGF-; lane 8, 0.25 M staurosporine (stauro). Upregulation of CHOP is only seen with
palmitic acid, whereas BiP is induced by palmitic acid and TGF- (faint band also for HG and M). -Actin served as a loading control. Representative results
of 4 independent experiments are shown.
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with CHOP-silencing shRNA after stimulation with tunicamy-
cin, an established inducer of the UPR (Fig. 6, A and B) or
palmitic acid (Fig. 6C). The suppression of BiP upregulation
(Fig. 6, A–C) was expected as CHOP knockdown leads to
lower levels of the UPR as a result of reduced translation,
resulting in decreased expression of BiP (31). Functionally, the
knockdown of CHOP significantly attenuated the palmitic
acid-induced cell death of podocytes (Fig. 6, D and F). These
findings are completely consistent with the important role of
CHOP in a murine model of DN as well as age-related
albuminuria (59). However, the role of CHOP may be more
complicated in humans with DN, as CHOP was not upregu-
lated by quantitative RT-PCR in the tubulointerstitial compart-
ment of patients with DN (22). Similarly, we found no upregu-
lation of CHOP mRNA expression in glomerular extracts from
eight patients with established DN where CHOP expression
was even reduced (Supplemental Fig. S2C).
DISCUSSION
The present study uncovered that saturated palmitic acid
induces podocyte cell death. Our findings are of clinical inter-
est because insulin resistance is associated with increased
plasma levels of long-chain FFAs, and DN is characterized by
Fig. 5. Palmitoleic or oleic acid prevent
palmitic acid-induced podocyte death and at-
tenuate CHOP induction. A: palmitoleic acid
blocks palmitic acid-induced podocyte cell
death (n 	 3, *P  0.05, **P  0.01, com-
pared with palmitic acid). B: palmitoleic acid
blocks palmitic acid-induced upregulation of
BiP and CHOP protein steady-state levels.
-Actin served as a loading control. Repre-
sentative result of 2 independent experiments
is shown. C: oleic acid blocks palmitic acid-
induced podocyte cell death (n 	 3, *P 
0.01 compared with palmitic acid). D: oleic
acid blocks palmitic acid-induced upregula-
tion of BiP and CHOP protein steady-state
levels. -Actin served as a loading control.
Representative result of 2 independent exper-
iments is shown.
Fig. 6. Gene silencing of CHOP protects
against palmitic acid-induced podocyte cell
death. A: gene-silencing of CHOP suppresses
the tunicamycin-induced upregulation of BiP
and CHOP protein levels. -Actin served as a
loading control. Representative result of 3
independent experiments are shown. B: quan-
titative analysis showing a significant reduc-
tion of tunicamycin-induced upregulation of
CHOP and BiP in cells infected with CHOP
short-hairpin (sh) RNA (*P  0.01, **P 
0.001). C: gene silencing of CHOP sup-
presses the palmitic acid-induced upregula-
tion of CHOP and BiP protein levels. Repre-
sentative result of 3 independent experiments
is shown. D–F: gene silencing of CHOP pro-
tects against palmitic acid-induced apoptosis
(D) and overall increase in cell death (F).
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apoptosis and loss of podocytes that precede albuminuria and
renal dysfunction in DN, both in type 1 and type 2 diabetes (9,
35, 42, 50, 53). Previous studies found that high glucose (50),
TGF- (62), the renin-angiotensin-aldosterone system (12, 14),
and advanced glycation end products (7) can also induce
apoptosis of podocytes.
The identification of palmitic acid as another proapoptotic
factor for podocytes may be of clinical relevance in the setting
of type 2 diabetes because FFAs are elevated in patients with
obesity and insulin resistance even before hyperglycemia arises
(4). FFAs can also be elevated in type 1 diabetic subjects (34).
Moreover, similar to DN, obesity-related glomerulonephropa-
thy is characterized by a decreased density of podocytes (5),
raising the intriguing possibility that FFA-induced podocyte
apoptosis may also contribute to the development and progres-
sion of obesity-related glomerular disease.
The detection of palmitic acid-induced ER stress in podo-
cytes is in line with similar findings in other cell types (15, 18,
33, 56, 57). In pancreatic  cells, the overexpression of the
ER-chaperon BiP can reduce palmitic acid-induced apoptosis
(20), implying that the upregulation of BiP (Fig. 4A) is part of
an adaptive podocyte-protective mechanism. In contrast, the
strong upregulation of CHOP (Fig. 4, B and C) makes CHOP
a good candidate as a mediator of palmitic acid-induced podo-
cyte apoptosis because CHOP is critically involved in ER
stress-induced apoptosis (31, 61). Consistent with the strong
induction of CHOP, we also observed palmitic acid-induced
XBP-1 splicing (Fig. 4D), which is directly involved in tran-
scriptional regulation of CHOP (41). Together, our data indi-
cate that the palmitic acid-induced upregulation of CHOP in
podocytes results, at least in part, from transcriptional activa-
tion of CHOP.
Another interesting outcome of the current study was the
finding that neither high glucose nor TGF- at a concentration
previously shown to induce podocyte apoptosis (45) caused an
upregulation of CHOP (Fig. 4E), suggesting that CHOP is not
involved in podocyte apoptosis induced by high glucose or
TGF-.
The antagonistic effects of palmitic acid and monounsatu-
rated palmitoleic acid or oleic acid on ER stress and apoptosis
of podocytes (Fig. 5) are in line with studies in other cells (10,
15, 28, 56). The addition of the monounsaturated FFAs to
palmitic acid could suppress the induction of CHOP (Fig. 5, B
and C), which may explain, at least in part, the prevention of
palmitic acid-induced podocyte apoptosis. In addition, we
consistently observed an increase in the ER chaperone BiP in
podocytes treated with monounsaturated palmitoleic or oleic
acid (Fig. 5, B and C). As BiP is known to protect from
palmitic acid-induced apoptosis (20), this may explain the
protective effect of monounsaturated FFAs.
The gene silencing of CHOP reduces palmitic acid-induced
podocyte death (Fig. 6, D–F), thereby establishing a causative
role for CHOP in palmitic acid-induced podocyte apoptosis.
This outcome is consistent with the known role of CHOP in ER
stress-induced apoptosis (31, 61). ER stress has been impli-
cated in podocyte apoptosis caused by advanced glycation end
products (6) or excessive protein loading (16), but a causative
role of CHOP under these conditions remains to be established.
The notion that CHOP plays a pathogenic role in experi-
mental DN is supported by the observation that CHOP is
upregulated in two rodent models of DN (24, 59), and CHOP-
deficient mice are protected from DN as well as age-related
albuminuria (59). However, in patients with DN, although we
found an upregulation of BiP by quantitative RT-PCR analysis
in the tubulointerstitial compartment (22) as well as in micro-
dissected glomeruli (Supplemental Fig. S2A), CHOP mRNA
expression was unchanged in the tubulointerstitial compart-
ment (22) and downregulated in glomeruli (Supplemental Fig.
2C). Clearly, future studies will be required to address potential
differences between our in vitro data, results in murine models,
and human DN to determine the precise role of CHOP in
patients with DN.
In conclusion, our results unveil the antagonistic effects of
palmitic acid vs. monounsaturated FFAs on podocyte survival,
ER stress, and the UPR. They support an important role of
CHOP in the regulation of podocyte cell death by FFAs. The
observed opposing effects of long-chain saturated and unsat-
urated FFAs on ER stress and podocyte viability provide a
rationale for interventional studies that will test whether the
progression of DN can be delayed by dietary shifting the FFA
balance toward unsaturated FFAs, e.g., by consumption of
peanuts and olive oil.
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